Untitled document
National Health (Listing of Pharmaceutical Benefits) Instrument 2012 (PB 71 of 2012)
made under sections 84AF, 84AK, 85, 85A, 88 and 101 of the
National Health Act 1953
Compilation No. 50
Compilation date: 1 December 2016
Includes amendments up to: PB 97 of 2016
Registered: 14 December 2016
This compilation is in 6 volumes
Volume 1: sections 1–26 and Schedule 1 (A–C)
Volume 2: Schedule 1 (D–K)
Volume 3: Schedule 1 (L–P)
Volume 4: Schedules 1 (Q–Z), 2 and 3
Volume 5: Schedule 4 (A–R)
Volume 6: Schedules 4 (S–Z), 5 and Endnotes
Each volume has its own contents
About this compilation
This compilation
This is a compilation of the National Health (Listing of Pharmaceutical Benefits) Instrument 2012 (PB 71 of 2012) that shows the text of the law as amended and in force on 1 December 2016 (the compilation date).
The notes at the end of this compilation (the endnotes) include information about amending laws and the amendment history of provisions of the compiled law.
Uncommenced amendments
The effect of uncommenced amendments is not shown in the text of the compiled law. Any uncommenced amendments affecting the law are accessible on the Legislation Register ( The details of amendments made up to, but not commenced at, the compilation date are underlined in the endnotes. For more information on any uncommenced amendments, see the series page on the Legislation Register for the compiled law.
Application, saving and transitional provisions for provisions and amendments
If the operation of a provision or amendment of the compiled law is affected by an application, saving or transitional provision that is not included in this compilation, details are included in the endnotes.
Editorial changes
For more information about any editorial changes made in this compilation, see the endnotes.
Modifications
If the compiled law is modified by another law, the compiled law operates as modified but the modification does not amend the text of the law. Accordingly, this compilation does not show the text of the compiled law as modified. For more information on any modifications, see the series page on the Legislation Register for the compiled law.
Self‑repealing provisions
If a provision of the compiled law has been repealed in accordance with a provision of the law, details are included in the endnotes.
Contents
1............................ Name of Instrument...................................................................................... 1
4............................ Definitions.................................................................................................... 1
5............................ Drugs and medicinal preparations to which Part VII applies........................ 2
6............................ Form............................................................................................................. 3
7............................ Manner of administration.............................................................................. 3
8............................ Brand and responsible person....................................................................... 3
8A......................... Schedule equivalent....................................................................................... 4
9............................ Authorised prescriber.................................................................................... 4
10.......................... Prescription circumstances—Schedule 1....................................................... 5
11.......................... Authority required procedures...................................................................... 5
12.......................... Authority required procedures—submission of prescription........................ 6
13.......................... Authority required procedures—authorisation.............................................. 7
14.......................... Streamlined authority code............................................................................ 8
15.......................... Extended application of sections 11 to 14..................................................... 8
16.......................... Prescription circumstances—Schedule 2....................................................... 8
17.......................... Maximum quantity—Schedule 1................................................................... 9
18.......................... Maximum quantity conditions—Schedule 1............................................... 10
19.......................... Maximum quantity—Schedule 2................................................................. 10
20.......................... Maximum number of repeats—Schedule 1................................................. 10
21.......................... Maximum number of repeats conditions—Schedule 1................................ 11
22.......................... Maximum number of repeats—Schedule 2................................................. 11
23.......................... Determined Quantity................................................................................... 11
24.......................... Pack Quantity.............................................................................................. 12
25.......................... Section 100 only supply.............................................................................. 12
26.......................... Prescriber bag only supply.......................................................................... 13
Schedule 1—Ready‑prepared pharmaceutical benefits 15
1 Name of Instrument
(1) This Instrument is the National Health (Listing of Pharmaceutical Benefits) Instrument 2012.
(2) This Instrument may also be cited as PB 71 of 2012.
4 Definitions
In this Instrument:
ABN has the same meaning as in the A New Tax System (Australian Business Number) Act 1999;
Act means the National Health Act 1953;
authorised prescriber for a pharmaceutical benefit, means a kind of person identified by a prescriber code mentioned in the column in Schedule 1 headed ‘Authorised Prescriber’ for the benefit;
CFC means chlorofluorocarbon;
CFU means colony forming unit;
circumstances code means the letter ‘C’ followed by a number;
conditions code means the letters ‘CN’ followed by a number;
electronic communication has the meaning given by subsection 5(1) of the Electronic Transactions Act 1999;
electronic prescription has the meaning given by the Regulations;
extemporaneously‑prepared pharmaceutical benefit means a pharmaceutical benefit other than a ready‑prepared pharmaceutical benefit;
General Statement for drugs for the treatment of hepatitis C means the statement set out in Part 3 of Schedule 4;
General Statement for Lipid‑Lowering Drugs means the statement set out in Part 2 of Schedule 4;
GP Management Plan means a comprehensive written plan for the treatment of a patient, prepared by a medical practitioner, that includes a description of the patient’s health care needs, management goals, actions to be taken by the patient and treatment and services the patient is likely to need;
I.M. means intramuscular;
I.U. means international unit;
I.V. means intravenous;
Medicare Benefits Schedule means the Health Insurance (General Medical Services Table) Regulations;
mmol means millimole;
palliative care patient means a patient with an active, progressive, far‑advanced disease for whom the prognosis is limited and the focus of care is the quality of life;
paper-based prescription has the meaning given by the Regulations;
PBS means Pharmaceutical Benefits Scheme;
prescriber code means any of the following codes identifying the kind of person mentioned for the code:
(a) MP—medical practitioner;
(b) PDP—participating dental practitioner;
(c) AO—authorised optometrist;
(d) MW—authorised midwife;
(e) NP—authorised nurse practitioner;
purposes code means the letter ‘P’ followed by a number;
ready‑prepared pharmaceutical benefit means a brand of a pharmaceutical item in relation to which a determination under subsection 85(6) of the Act is in force;
Regulations means the National Health (Pharmaceutical Benefits) Regulations 1960;
residential care service has the meaning given by the Regulations;
Streamlined Authority Code means the words ‘Streamlined Authority Code’ followed by a number;
Team Care Arrangements means a document prepared by a medical practitioner, following consultation with collaborating providers, that includes a description of the treatment and service goals for the patient, the treatment and services that all collaborating providers will provide and the actions to be taken by the patient;
TGA means Therapeutic Goods Administration;
WHO means World Health Organisation.
Note: Terms used in this Instrument have the same meaning as in the Act—see section 13 of the Legislative Instruments Act 2003. These terms include:
· Chief Executive Medicare
· pharmaceutical benefit
· pharmaceutical item.
5 Drugs and medicinal preparations to which Part VII applies
(1) For paragraph 85(2)(a) of the Act, Part VII of the Act applies to:
(a) a drug or medicinal preparation mentioned in the column headed ‘Listed Drug’ in:
(i) Schedule 1; or
(ii) Part 1 of Schedule 2; and
(b) a medicinal preparation composed of 1 or more listed drugs mentioned in subparagraph (a)(ii).
(2) For subparagraph 85(2)(b)(i) of the Act, paragraph 85(2)(b) of the Act applies to a listed drug mentioned in subparagraph (1)(a)(ii).
(3) For subparagraph 85(2)(b)(ii) of the Act, paragraph 85(2)(b) of the Act applies to an additive mentioned in Part 2 of Schedule 2.
Note: Part VII of the Act applies to medicinal preparations composed of 1 or more listed drugs mentioned in subsection (2) and 1 or more of the additives mentioned in subsection (3)—see paragraph 85(2)(b) of the Act.
6 Form
For subsection 85(3) of the Act, the column headed ‘Form’ in Schedule 1 lists the form or forms for a listed drug determined for that drug.
7 Manner of administration
(1) For subsection 85(5) of the Act, the manner of administration of a form of a listed drug mentioned in Schedule 1 is the manner of administration mentioned for that form of the drug in the column headed ‘Manner of Administration’ in Schedule 1.
(2) For paragraph 85A(2)(c) of the Act, if a manner of administration is mentioned in Schedule 1 for a form of a listed drug, a person writing a prescription for the supply of a pharmaceutical benefit that has the listed drug in that form must, if including a manner of administration in the prescription, direct that the pharmaceutical benefit be administered in that manner.
(3) For subsection (2), the pharmaceutical benefit is the brand of the listed drug mentioned in Schedule 1:
(a) in the form mentioned in Schedule 1 for the listed drug; and
(b) with the manner of administration mentioned in Schedule 1 for the form of the listed drug.
8 Brand and responsible person
(1) A brand mentioned in the column headed ‘Brand’ in Schedule 1 for a pharmaceutical item is determined for subsection 85(6) of the Act for that pharmaceutical item.
(2) For subsection 84AF(1) of the Act, if a code is mentioned in the column in Schedule 1 headed ‘Responsible Person’ for a brand of a pharmaceutical item, the person mentioned in subsection (3) is the responsible person for the brand of the pharmaceutical item.
(3) For subsection (2), the person is the person mentioned in Schedule 3 for the code, with the ABN, if any, mentioned in Schedule 3 for the person.
(4) For subsections (1) and (2), the pharmaceutical item is the listed drug mentioned in Schedule 1:
(a) in the form mentioned in Schedule 1 for the listed drug; and
(b) with the manner of administration mentioned in Schedule 1 for the form of the listed drug.
8A Schedule equivalent
(1) For subsection 85(6A) of the Act:
(a) a brand of a pharmaceutical item with an ‘a’ located in the column headed ‘Schedule Equivalent’ in Schedule 1, is to be treated as equivalent to another brand of that pharmaceutical item that also has an ‘a’ located in the column headed ‘Schedule Equivalent’ in Schedule 1;
(b) where paragraph (a) applies to a brand of a pharmaceutical item, a brand of the same pharmaceutical item with a ‘b’ in the column headed ‘Schedule equivalent’ in Schedule 1, is to be treated as equivalent to another brand of that pharmaceutical item that also has a ‘b’ located in the column headed ‘Schedule Equivalent’ in Schedule 1; and
(c) where a brand of a pharmaceutical item appears in Schedule 5, that brand is to be treated as equivalent to any brand of any pharmaceutical item that is in the same schedule equivalent group as that brand in Schedule 5.
9 Authorised prescriber
(1) For subsection 88(1A) of the Act, a participating dental practitioner is authorised to write a prescription for the supply of a pharmaceutical benefit if the initials PDP are mentioned for the pharmaceutical benefit in the column headed ‘Authorised Prescriber’ in Schedule 1.
(2) For subsection 88(1C) of the Act, an authorised optometrist is authorised to write a prescription for the supply of a pharmaceutical benefit if the initials AO are mentioned for the pharmaceutical benefit in the column headed ‘Authorised Prescriber’ in Schedule 1.
(3) For subsection 88(1D) of the Act, an authorised midwife is authorised to write a prescription for the supply of a pharmaceutical benefit if the initials MW are mentioned for the pharmaceutical benefit in the column headed ‘Authorised Prescriber’ in Schedule 1.
(4) For subsection 88(1E) of the Act, an authorised nurse practitioner is authorised to write a prescription for the supply of a pharmaceutical benefit if the initials NP are mentioned for the pharmaceutical benefit in the column headed ‘Authorised Prescriber’ in Schedule 1.
(5) For this section, the pharmaceutical benefit is the brand of the listed drug mentioned in Schedule 1:
(a) in the form mentioned in Schedule 1 for the listed drug; and
(b) with the manner of administration mentioned in Schedule 1 for the form of the listed drug.
Note: A medical practitioner may prescribe any pharmaceutical benefit—see subsection 88(1) of the Act.
10 Prescription circumstances—Schedule 1
(1) This section applies to a pharmaceutical benefit if at least 1 circumstances code is mentioned in the column in Schedule 1 headed ‘Circumstances’ for the pharmaceutical benefit.
(2) For paragraph 85(7)(a) of the Act, the pharmaceutical benefit is a relevant pharmaceutical benefit for the purposes of section 88A of the Act.
(3) For paragraph 85(7)(b) of the Act, the circumstances in which a prescription for the supply of the pharmaceutical benefit may be written are the circumstances mentioned in Part 1 of Schedule 4 for at least 1 of the circumstances codes mentioned in Schedule 1 for the pharmaceutical benefit.
(4) For subsection (1), the pharmaceutical benefit is the brand of the listed drug mentioned in Schedule 1:
(a) in the form mentioned in Schedule 1 for the listed drug; and
(b) with the manner of administration mentioned in Schedule 1 for the form of the listed drug.
11 Authority required procedures
(1) This section applies to a pharmaceutical benefit if the circumstances mentioned in Part 1 of Schedule 4 for a circumstances code mentioned in Schedule 1 for the pharmaceutical benefit include any of the following:
(a) Compliance with Authority Required procedures;
(b) Compliance with Written Authority Required procedures;
(c) Compliance with Telephone Authority Required procedures;
(d) Compliance with Written or Telephone Authority Required procedures.
(1A) If the circumstances mentioned in Part 1 of Schedule 4 for a circumstances code mentioned in Schedule 1 for the pharmaceutical benefit include the words ‘Compliance with Telephone Authority Required procedures’ or ‘Compliance with Written or Telephone Authority Required procedures’ treat as if the words used are ‘Compliance with Authority Required procedures’.
Note: If there is a Streamlined Authority Code section 14 continues to apply.
(2) A prescription for the supply of the pharmaceutical benefit must be:
(a) submitted by the authorised prescriber to the Chief Executive Medicare in accordance with section 12; and
(b) authorised by the Chief Executive Medicare in accordance with section 13.
(3) In all circumstances mentioned in Part 1 of Schedule 4 for a circumstances code mentioned in Schedule 1 for the pharmaceutical benefit, except those which include a Streamlined Authority Code, a medication chart prescription for a person receiving treatment in a residential care service may not be authorised under the authority required procedures in sections 11 to 15.
12 Authority required procedures—submission of prescription
(1) A prescription is submitted in accordance with this subsection if:
(a) the authorised prescriber submits to the Chief Executive Medicare:
(i) the prescription itself; or
(ii) for a medication chart prescription that is not an electronic prescription — the medication chart by which the prescription was written, or a copy of so much of that chart as would indicate that subregulation 19AA(2) of the Regulations has been complied with; or
(b) the authorised prescriber submits details of the prescription by telephone to the Chief Executive Medicare; or
(c) the authorised prescriber submits the prescription in accordance with the instructions in an emergency telephone message provided to the authorised prescriber by the Chief Executive Medicare; or
(d) the authorised prescriber submits details of the prescription in accordance with subsection 12(4A) to the Chief Executive Medicare, by means of electronic communication to obtain an electronic authority.
(2) If a circumstance mentioned in Part 1 of Schedule 4 for a circumstances code applying to the pharmaceutical benefit includes Compliance with Written Authority Required procedures, the authorised prescriber must submit a prescription for the supply of the pharmaceutical benefit to the Chief Executive Medicare in accordance with paragraph (1)(a).
(3) If a circumstance mentioned in Part 1 of Schedule 4 for a circumstances code applying to the pharmaceutical benefit includes Compliance with Telephone Authority Required procedures, the authorised prescriber must submit a prescription for the supply of the pharmaceutical benefit to the Chief Executive Medicare in accordance with paragraph (1)(b) or (c).
(4) If a circumstance mentioned in Part 1 of Schedule 4 for a circumstances code applying to the pharmaceutical benefit includes Compliance with Written or Telephone Authority Required procedures, the authorised prescriber must submit a prescription for the supply of the pharmaceutical benefit to the Chief Executive Medicare in accordance with paragraph (1)(a), (b) or (c).
(4A) The prescription submitted in accordance with paragraph 12(1)(d) must be:
(a) given to the Chief Executive Medicare in writing; and
(b) by means of an electronic communication; and
(c) encrypted when it is given to the Chief Executive Medicare; and
(d) in accordance with any other requirements that would need to be met in order for the requirements to give the information in writing to be taken to have been met under the Electronic Transactions Act 1999.
(5) For paragraph (1)(a), a prescription prepared and signed by the authorised prescriber in accordance with subsection (1) is taken to have been submitted by the authorised prescriber if it is submitted by his or her employee.
13 Authority required procedures—authorisation
(1) A paper-based prescription (other than a prescription submitted in accordance with paragraph 12(1)(b), (c) or (d)) may be authorised by the Chief Executive Medicare signing his or her authorisation on the prescription, and:
(a) if the Chief Executive Medicare requires the authorised prescriber to alter the prescription — returning it to the authorised prescriber for alteration before the authorised prescriber gives it to the person in respect of whom it was prepared; or
(b) by returning it to the authorised prescriber; or
(c) if requested by the authorised prescriber — sending it to the person in respect of whom it was prepared.
(1A) A medication chart prescription (other than an electronic prescription, or a prescription submitted in accordance with paragraphs 12(1)(b), (c) or (d)) may be authorised by the Chief Executive Medicare signing his or her authorisation on the medication chart prescription, or a copy of the medication chart prescription, and:
(a) if the Chief Executive Medicare requires the authorised prescriber to alter the prescription— indicating this on the medication chart prescription or copy; and
(b) returning the medication chart or copy to the authorised prescriber for alteration.
(1B) An electronic prescription (other than a prescription submitted in accordance with paragraphs 12(1)(b), (c) or (d)) may be authorised by the Chief Executive Medicare writing his or her authorisation on the electronic prescription, and:
(a) if the Chief Executive Medicare requires the authorised prescriber to alter the prescription— by returning it, including by means of an electronic communication, to the authorised prescriber for alteration; or
(b) by returning it, including by means of electronic communication to the authorised prescriber; or
(c) if requested by the authorised prescriber — sending it to the person in respect of whom it was prepared.
(2) A prescription submitted in accordance with paragraph 12(1)(b) may be authorised by the Chief Executive Medicare telling the authorised prescriber by telephone, at the time the Chief Executive Medicare is given details of the prescription, that the prescription is authorised.
(3) A prescription submitted in accordance with paragraph 12(1)(d) may be authorised by the Chief Executive Medicare sending his or her authorisation, by electronic communication, including computer automated electronic communication, to the authorised prescriber.
(3A) If the prescription submitted is declined for authorisation, the authorised prescriber may seek review of the decision by the Chief Executive Medicare.
(4) If the Chief Executive Medicare authorises a prescription under subsection (2) or (3):
(a) the Chief Executive Medicare must tell the authorised prescriber the number that has been allotted to the authorised prescription: and
(b) the authorised prescriber must:
(i) mark that number on the prescription; and
(ii) retain a copy of the prescription showing the number marked in accordance with subparagraph (i) for 1 year from the date the prescription was authorised.
(5) For paragraph (4)(a), the Chief Executive Medicare must tell the authorised prescriber the number:
(i) if the authorised prescriber is an authorised optometrist—by telephone; and
(ii) in any other case—by telephone or by electronic communication.
(6) A prescription submitted in accordance with paragraph 12(1)(c) is taken to have been authorised by the Chief Executive Medicare if the authorised prescriber completes the prescription in accordance with the instructions given in the emergency telephone message.
14 Streamlined authority code
(1) This section applies to a pharmaceutical benefit if the circumstances mentioned in Schedule 4 for a circumstances code applying to the pharmaceutical benefit include a Streamlined Authority Code.
(2) The requirements of section 12 are taken to have been complied with, and the Chief Executive Medicare is taken to have authorised the prescription of the pharmaceutical benefit under section 13, if the authorised prescriber has written the Streamlined Authority Code on the prescription.
15 Extended application of sections 11 to 14
Sections 11 to 14 apply in relation to conditions and conditions codes as if the circumstances and circumstances codes mentioned in those sections were conditions and conditions codes.
Note: Conditions are determined in sections 18 and 21.
16 Prescription circumstances—Schedule 2
(1) For paragraph 85(7)(a) of the Act, a pharmaceutical benefit is a relevant pharmaceutical benefit for the purposes of section 88A if:
(a) it is:
(i) a listed drug mentioned in Part 1 of Schedule 2; or
(ii) an extemporaneously‑prepared pharmaceutical benefit that contains the listed drug; and
(b) there are circumstances mentioned for the listed drug in the column headed ‘Circumstances’ in Part 1 of Schedule 2.
(2) For paragraph 85(7)(b) of the Act, the circumstances in which a prescription for the supply of a pharmaceutical benefit mentioned in subsection (1) may be written are:
(a) for a listed drug mentioned in subparagraph (1)(a)(i)—the circumstances mentioned in the column headed ‘Circumstances’ in Part 1 of Schedule 2 for the drug; and
(b) for an extemporaneously‑prepared pharmaceutical benefit mentioned in subparagraph (1)(a)(ii)—the circumstances mentioned in the column headed ‘Circumstances’ in Part 1 of Schedule 2 for each listed drug contained in the pharmaceutical benefit.
Note: If an extemporaneously‑prepared pharmaceutical benefit contains more than one listed drug, a prescription for the supply of the pharmaceutical benefit may only be written if the circumstances mentioned for each of the listed drugs contained in the pharmaceutical benefit are met.
17 Maximum quantity—Schedule 1
(1) For paragraph 85A(2)(a) of the Act, the maximum quantity or number of units of the pharmaceutical item in a pharmaceutical benefit mentioned in Schedule 1 that may, in 1 prescription for the supply of the pharmaceutical benefit, be directed by an authorised prescriber to be supplied on any 1 occasion is the quantity or number of units mentioned in the column in Schedule 1 headed ‘Maximum Quantity’ for the pharmaceutical benefit and authorised prescriber.
(2) If at least 1 purposes code is mentioned in the column in Schedule 1 headed ‘Purposes’ for a pharmaceutical benefit, the quantity or number of units mentioned in the column headed ‘Maximum Quantity’ is the maximum for the particular purposes mentioned in Schedule 4 for each purposes code.
(3) If no purposes code is mentioned in the column in Schedule 1 headed ‘Purposes’, the quantity or number of units mentioned in the column in Schedule 1 headed ‘Maximum Quantity’ is the maximum for all purposes, other than a purpose for which a different maximum is mentioned for the same pharmaceutical benefit.
(4) For subsection (1) the pharmaceutical item is the listed drug mentioned in Schedule 1:
(a) in the form mentioned in Schedule 1 for the listed drug; and
(b) with the manner of administration mentioned in Schedule 1 for the form of the listed drug.
(5) For this section, the pharmaceutical benefit is the brand of the listed drug mentioned in Schedule 1:
(a) in the form mentioned in Schedule 1 for the listed drug; and
(b) with the manner of administration mentioned in Schedule 1 for the form of the listed drug.
18 Maximum quantity conditions—Schedule 1
(1) This section applies to a pharmaceutical benefit if a conditions code is mentioned in the column in Schedule 1 headed ‘Maximum Quantity’ for a maximum quantity or number of units for the pharmaceutical benefit.
(2) For subsection 85A(2A) of the Act, the conditions which must be satisfied when writing a prescription for the supply of the pharmaceutical benefit to which a determination of a maximum quantity or number of units under paragraph 85A(2)(a) applies, are the conditions mentioned in Part 1 of Schedule 4 for the conditions code mentioned in Schedule 1 for the pharmaceutical benefit and the maximum quantity or number of units.
(3) For this section, the pharmaceutical benefit is the brand of the listed drug mentioned in Schedule 1:
(a) in the form mentioned in Schedule 1 for the listed drug; and
(b) with the manner of administration mentioned in Schedule 1 for the form of the listed drug.
19 Maximum quantity—Schedule 2
(1) For paragraph 85A(2)(a) of the Act, the maximum quantity or number of units of an extemporaneously‑prepared pharmaceutical benefit of a type mentioned in Part 3 of Schedule 2 that may, in 1 prescription for the supply of the pharmaceutical benefit, be directed by an authorised prescriber to be supplied on any 1 occasion is the quantity or number of units mentioned in the column headed ‘Maximum Quantity’ in Part 3 of Schedule 2 for that type of pharmaceutical benefit.
(2) For subsection (1), the extemporaneously‑prepared pharmaceutical benefit is:
(a) the listed drug mentioned in Part 1 of Schedule 2; or
(b) an extemporaneously‑prepared pharmaceutical benefit that contains the listed drug.
20 Maximum number of repeats—Schedule 1
(1) For paragraph 85A(2)(b) of the Act, the maximum number of occasions an authorised prescriber may, in 1 prescription, direct that the supply of a pharmaceutical benefit mentioned in Schedule 1 be repeated is the number in the column in Schedule 1 headed ‘Number of Repeats’ for the pharmaceutical benefit and the authorised prescriber.
(2) If at least 1 purposes code is mentioned in the column in Schedule 1 headed ‘Purposes’ for the pharmaceutical benefit, the number of repeats mentioned in the column in Schedule 1 headed ‘Number of Repeats’ is the maximum for the particular purposes mentioned in Schedule 4 for each purposes code.
(3) If no purposes code is mentioned in the column headed ‘Purposes’, the number of repeats mentioned in the column headed ‘Number of Repeats’ is the maximum for all purposes, other than a purpose for which a different maximum is mentioned for the same pharmaceutical benefit.
(4) For this section, the pharmaceutical benefit is the brand of the listed drug mentioned in Schedule 1:
(a) in the form mentioned in Schedule 1 for the listed drug; and
(b) with the manner of administration mentioned in Schedule 1 for the form of the listed drug.
21 Maximum number of repeats conditions—Schedule 1
(1) This section applies to a pharmaceutical benefit if a conditions code is mentioned in the column in Schedule 1 headed ‘Number of Repeats’ for the maximum number of repeats for the pharmaceutical benefit.
(2) For subsection 85A(2A) of the Act, the conditions which must be satisfied when writing a prescription for the supply of the pharmaceutical benefit to which a determination of a maximum number of repeats under paragraph 85A(2)(b) applies, are the conditions mentioned in Part 1 of Schedule 4 for the conditions code mentioned in Schedule 1 for the pharmaceutical benefit and the maximum number of repeats.
(3) For this section, the pharmaceutical benefit is the brand of the listed drug mentioned in Schedule 1:
(a) in the form mentioned in Schedule 1 for the listed drug; and
(b) with the manner of administration mentioned in Schedule 1 for the form of the listed drug.
22 Maximum number of repeats—Schedule 2
(1) For paragraph 85A(2)(b) of the Act, the maximum number of occasions an authorised prescriber may, in 1 prescription, direct that the supply of an extemporaneously‑prepared pharmaceutical benefit of a type mentioned in Part 3 of Schedule 2 be repeated is the number in the column headed ‘Number of Repeats’ in Part 3 of Schedule 2 for that type of pharmaceutical benefit.
(2) For this section, the extemporaneously‑prepared pharmaceutical benefit is:
(a) the listed drug mentioned in Part 1 of Schedule 2; or
(b) an extemporaneously‑prepared pharmaceutical benefit that contains the listed drug.
23 Determined Quantity
(1) For subsection 84AK(3) of the Act, the quantities or numbers of units of a pharmaceutical item that are determined quantities of a listed brand of the pharmaceutical item mentioned in Schedule 1 are the quantities or numbers of units mentioned in the column in Schedule 1 headed ‘Determined Quantity’ for the listed brand of the pharmaceutical item.
(2) For this section, the listed brand of the pharmaceutical item is the brand of the listed drug mentioned in Schedule 1:
(a) in the form mentioned in Schedule 1 for the listed drug; and
(b) with the manner of administration mentioned in Schedule 1 for the form of the listed drug.
(3) For this section, the pharmaceutical item is the listed drug mentioned in Schedule 1:
(a) in the form mentioned in Schedule 1 for the listed drug; and
(b) with the manner of administration mentioned in Schedule 1 for the form of the listed drug.
24 Pack Quantity
(1) For subsection 84AK(2) of the Act, the quantities or numbers of units of a pharmaceutical item that are pack quantities of a listed brand of the pharmaceutical item mentioned in Schedule 1 are the quantities or numbers of units mentioned in the column in Schedule 1 headed ‘Pack Quantity’ for the listed brand of the pharmaceutical item.
(2) For this section, the listed brand of the pharmaceutical item is the brand of the listed drug mentioned in Schedule 1:
(a) in the form mentioned in Schedule 1 for the listed drug; and
(b) with the manner of administration mentioned in Schedule 1 for the form of the listed drug.
(3) For this section, the pharmaceutical benefit is the brand of the listed drug mentioned in Schedule 1:
(a) in the form mentioned in Schedule 1 for the listed drug; and
(b) with the manner of administration mentioned in Schedule 1 for the form of the listed drug.
25 Section 100 only supply
(1) For subsection 85(2A) of the Act, if the code D(100) is mentioned in the column headed ‘Section 100/Prescriber Bag only’ in Schedule 1 for a listed drug, the drug can only be supplied under special arrangements under section 100 of the Act.
(2) For paragraph 85(8)(a) of the Act, if the code PB(100) is mentioned in the column headed ‘Section 100/Prescriber Bag only’ in Schedule 1 for a pharmaceutical benefit, the pharmaceutical benefit can only be supplied under special arrangements under section 100 of the Act.
(3) For paragraph 85(8)(b) of the Act, if the code C(100) is mentioned in the column headed ‘Section 100/Prescriber Bag only’ in Schedule 1 for a pharmaceutical benefit, and a circumstances code is mentioned for the pharmaceutical benefit in the column headed ‘Circumstances’, the pharmaceutical benefit can be supplied in the circumstances identified in Part 1 of Schedule 4 for the circumstances code only under special arrangements under section 100 of the Act.
(4) For this section, the pharmaceutical benefit is the brand of the listed drug mentioned in Schedule 1:
(a) in the form mentioned in Schedule 1 for the listed drug; and
(b) with the manner of administration mentioned in Schedule 1 for the form of the listed drug.
26 Prescriber bag only supply
(1) For subsection 85(2AA) of the Act, if one or more of the codes D(MP), D(MW) and D(NP) are mentioned in the column headed ‘Section 100/ Prescriber Bag only’ in Schedule 1 for a listed drug other than the drug methoxyflurane, then, subject to subsection (3), the drug can only be supplied by:
(a) where the code D(MP) is mentioned, medical practitioners under section 93 of the Act, and
(b) where the code D(MW) is mentioned, authorised midwives under section 93AA of the Act, and
(c) where the code D(NP) is mentioned, authorised nurse practitioners under section 93AB of the Act.
Note: A declaration in force immediately before 1 October 2012 for the purposes of subsection 85(2A) of the Act declaring that the drug methoxyflurane can only be supplied under special arrangements under section 100 of the Act, continues in force and may be dealt with on and after 1 October 2012, as if the declaration had been made for the purposes of subsection 85(2AA) of the Act and declared that methoxyflurane can only be supplied under section 93 of the Act (see Item 18 of Schedule 3 to the National Health Amendment (Pharmaceutical Benefits Scheme) Act 2012).
(2) For subsection 85(7A) of the Act, if one or more of the codes PB(MP), PB(MW) and PB(NP) are mentioned in the column headed ‘Section 100/ Prescriber Bag only’ in Schedule 1 for a pharmaceutical benefit, then, subject to subsection (3), the pharmaceutical benefit can only be supplied by:
(a) where the code PB(MP) is mentioned, medical practitioners under section 93 of the Act, and
(b) where the code PB(MW) is mentioned, authorised midwives under section 93AA of the Act, and
(c) where the code PB(NP) is mentioned, authorised nurse practitioners under section 93AB of the Act.
(3) If :
(a) one or more of the codes D(MP), D(MW), and D(NP) are mentioned in the column headed ‘Section 100/Prescriber Bag only’ in Schedule 1 for a listed drug; and
(b) one or more of the codes PB(MP), PB(MW) and PB(NP) are also mentioned in the column headed ‘Section 100/Prescriber Bag only’ in Schedule 1 for a pharmaceutical benefit having the listed drug;
then:
(c) the drug may be supplied as provided in subsection (1): and
(d) the pharmaceutical benefit may be supplied as provided in subsection (2).
(4) For this section, the pharmaceutical benefit is the brand of the listed drug mentioned in Schedule 1:
(a) in the form mentioned in Schedule 1 for the listed drug; and
(b) with the manner of administration mentioned in Schedule 1 for the form of the listed drug.
Schedule 1—Ready‑prepared pharmaceutical benefits
(sections 5 to 10, 16 to 18, 20, 21, 23 to 26)
Listed Drug Form Manner of Administration Schedule Equivalent Brand Responsible Person Authorised Prescriber Circumstances Purposes Maximum Quantity Number of Repeats Pack Quantity Determined Quantity Section 100/ Prescriber Bag only Abacavir Tablet 300 mg (as sulfate) Oral Ziagen VI MP C4454 C4512 120 5 60 D(100) Oral solution 20 mg (as sulfate) per mL, 240 mL Oral Ziagen VI MP C4454 C4512 8 5 1 D(100) Abacavir with Lamivudine Tablet containing abacavir 600 mg (as sulfate) with lamivudine 300 mg Oral Kivexa VI MP C4527 C4528 60 5 30 D(100) Abacavir with Lamivudine and Zidovudine Tablet containing abacavir 300 mg (as sulfate) with lamivudine 150 mg and zidovudine 300 mg Oral Trizivir VI MP C4480 C4495 120 5 60 D(100) Abatacept Injection 125 mg in 1 mL single dose pre‑filled syringe Injection Orencia BQ MP C4720 C4746 C5448 C5495 C5503 P4746 P5448 P5495 4 3 4 MP C4720 C4746 C5448 C5495 C5503 P4720 P5503 4 5 4 Powder for I.V. infusion 250 mg Injection Orencia BQ MP See Note 3 See Note 3 See Note 3 See
Note 31 PB(100) Abciximab I.V. injection 10 mg in 5 mL vial Injection ReoPro LY MP C4915 C4942 C4943 3 0 1 Abiraterone Tablet containing abiraterone acetate 250 mg Oral Zytiga JC MP C4654 120 2 120 Acamprosate Tablet (enteric coated) containing acamprosate calcium 333 mg Oral Campral AF MP NP C5366 180 1 180 Acarbose Tablet 50 mg Oral a Acarbose Mylan AF MP NP 90 5 90 a Glucobay 50 BN MP NP 90 5 90 a GLYBOSAY RW MP NP 90 5 90 Tablet 100 mg Oral a Acarbose Mylan AF MP NP 90 5 90 a Glucobay 100 BN MP NP 90 5 90 a GLYBOSAY RW MP NP 90 5 90 Acetazolamide Tablet 250 mg Oral Diamox RW MP NP 100 3 100 Aciclovir Eye ointment 30 mg per g, 4.5 g Application to the eye AciVision DZ MP NP C5965 1 0 1 AO C5964 1 0 1 Zovirax GK MP NP C5965 1 0 1 AO C5964 1 0 1 Tablet 200 mg Oral a Aciclovir Sandoz HX MP NP C5936 C5942 P5936 50 0 25 a Acyclo‑V 200 AF MP NP C5936 C5942 P5936 50 0 25 a GenRx Aciclovir GX MP NP C5936 C5942 P5936 50 0 50 a Aciclovir 200 CR MP NP C5942 90 5 90 a Aciclovir GH GQ MP NP C5942 90 5 90 a Aciclovir Sandoz HX MP NP C5936 C5942 P5942 90 5 90 a Acyclo‑V 200 AF MP NP C5936 C5942 P5942 90 5 90 a Chem mart Aciclovir CH MP NP C5942 90 5 90 a GenRx Aciclovir GX MP NP C5936 C5942 P5942 90 5 90 a Lovir EA MP NP C5942 90 5 90 a Ozvir RA MP NP C5942 90 5 90 a Terry White Chemists Aciclovir TW MP NP C5942 90 5 90 a Zovirax 200 mg GK MP NP C5942 90 5 90 Tablet 800 mg Oral a Aciclovir 800 CR MP NP C5959 C5967 35 0 35 a Aciclovir Sandoz HX MP NP C5959 C5967 35 0 35 a Acyclo‑V 800 AF MP NP C5946 C5959 C5967 P5959 P5967 35 0 35 a GenRx Aciclovir GX MP NP C5959 C5967 35 0 35 Acyclo‑V 800 AF MP NP C5946 C5959 C5967 P5946 120 5 120 Acitretin Capsule 10 mg Oral Acitretin Actavis GN MP C5727 C5789 100 2 100 Neotigason UA MP C5727 C5789 100 2 100 Novatin TX MP C5727 C5789 100 2 100 Capsule 25 mg Oral Acitretin Actavis GN MP C5727 C5789 100 2 100 Neotigason UA MP C5727 C5789 100 2 100 Novatin TX MP C5727 C5789 100 2 100 Aclidinium Powder for oral inhalation in breath actuated device 322 micrograms (as bromide) per dose, 60 doses Inhalation by mouth Bretaris Genuair FK MP NP C4516 1 5 1 Aclidinium with eformoterol Powder for oral inhalation in breath actuated device containing aclidinium 340 micrograms (as bromide) with eformoterol fumarate dihydrate 12 micrograms per dose, 60 doses Inhalation by mouth Brimica Genuair FK MP NP C5763 1 5 1 Adalimumab Injection 20 mg in 0.4 mL pre‑filled syringe Injection Humira VE MP See Note 3 See Note 3 See Note 3 See
Note 32 C(100) MP C5076 C5091 C5105 C5116 C5117 P5105 2 0 2 MP C5076 C5091 C5105 C5116 C5117 P5076 P5117 2 3 2 MP C5076 C5091 C5105 C5116 C5117 P5091 P5116 2 5 2 Injection 40 mg in 0.8 mL pre‑filled syringe Injection Humira VE MP See Note 3 See Note 3 See Note 3 See
Note 32 C(100) MP C3695 C3697 C3747 C3748 C4492 C4501 C4517 C4518 C4531 C4610 C4643 C4700 C4724 C4845 C4851 C5074 C5075 C5076 C5090 C5091 C5105 C5115 C5116 C5117 C5144 C5184 C5223 C5265 C5294 C5335 C5336 C5369 C5441 C5514 C5515 C6423 C6430 C6437 C6439 C6445 C6458 C6571 C6575 C6579 C6602 C6614 C6615 P5105 2 0 2 MP C3695 C3697 C3747 C3748 C4492 C4501 C4517 C4518 C4531 C4610 C4643 C4700 C4724 C4845 C4851 C5074 C5075 C5076 C5090 C5091 C5105 C5115 C5116 C5117 C5144 C5184 C5223 C5265 C5294 C5335 C5336 C5369 C5441 C5514 C5515 C6423 C6430 C6437 C6439 C6445 C6458 C6571 C6575 C6579 C6602 C6614 C6615 P3695 P3747 P5074 P5076 P5090 P5115 P5117 P6575 P6602 P6615 2 2 2 MP C3695 C3697 C3747 C3748 C4492 C4501 C4517 C4518 C4531 C4610 C4643 C4700 C4724 C4845 C4851 C5074 C5075 C5076 C5090 C5091 C5105 C5115 C5116 C5117 C5144 C5184 C5223 C5265 C5294 C5335 C5336 C5369 C5441 C5514 C5515 C6423 C6430 C6437 C6439 C6445 C6458 C6571 C6575 C6579 C6602 C6614 C6615 P4492 P4501 P4518 P4610 P4700 P4851 P5441 P5514 P6430 P6437 P6445 P6458 2 3 2 MP C3695 C3697 C3747 C3748 C4492 C4501 C4517 C4518 C4531 C4610 C4643 C4700 C4724 C4845 C4851 C5074 C5075 C5076 C5090 C5091 C5105 C5115 C5116 C5117 C5144 C5184 C5223 C5265 C5294 C5335 C5336 C5369 C5441 C5514 C5515 C6423 C6430 C6437 C6439 C6445 C6458 C6571 C6575 C6579 C6602 C6614 C6615 P5144 P5184 P5223 P5294 P5335 2 4 2 MP C3695 C3697 C3747 C3748 C4492 C4501 C4517 C4518 C4531 C4610 C4643 C4700 C4724 C4845 C4851 C5074 C5075 C5076 C5090 C5091 C5105 C5115 C5116 C5117 C5144 C5184 C5223 C5265 C5294 C5335 C5336 C5369 C5441 C5514 C5515 C6423 C6430 C6437 C6439 C6445 C6458 C6571 C6575 C6579 C6602 C6614 C6615 P3697 P3748 P4517 P4531 P4643 P4724 P4845 P5075 P5091 P5116 P5265 P5336 P5369 P5515 P6423 P6439 P6571 P6579 P6614 2 5 2 Injection 40 mg in 0.8 mL pre‑filled pen Injection Humira VE MP See Note 3 See Note 3 See Note 3 See
Note 32 C(100) MP C3695 C3697 C3747 C3748 C4492 C4501 C4517 C4518 C4531 C4610 C4643 C4700 C4724 C4845 C4851 C5074 C5075 C5076 C5090 C5091 C5105 C5115 C5116 C5117 C5144 C5184 C5223 C5265 C5294 C5335 C5336 C5369 C5441 C5514 C5515 C6423 C6430 C6437 C6439 C6445 C6458 C6571 C6575 C6579 C6602 C6614 C6615 P5105 2 0 2 MP C3695 C3697 C3747 C3748 C4492 C4501 C4517 C4518 C4531 C4610 C4643 C4700 C4724 C4845 C4851 C5074 C5075 C5076 C5090 C5091 C5105 C5115 C5116 C5117 C5144 C5184 C5223 C5265 C5294 C5335 C5336 C5369 C5441 C5514 C5515 C6423 C6430 C6437 C6439 C6445 C6458 C6571 C6575 C6579 C6602 C6614 C6615 P3695 P3747 P5074 P5076 P5090 P5115 P5117 P6575 P6602 P6615 2 2 2 MP C3695 C3697 C3747 C3748 C4492 C4501 C4517 C4518 C4531 C4610 C4643 C4700 C4724 C4845 C4851 C5074 C5075 C5076 C5090 C5091 C5105 C5115 C5116 C5117 C5144 C5184 C5223 C5265 C5294 C5335 C5336 C5369 C5441 C5514 C5515 C6423 C6430 C6437 C6439 C6445 C6458 C6571 C6575 C6579 C6602 C6614 C6615 P4492 P4501 P4518 P4610 P4700 P4851 P5441 P5514 P6430 P6437 P6445 P6458 2 3 2 MP C3695 C3697 C3747 C3748 C4492 C4501 C4517 C4518 C4531 C4610 C4643 C4700 C4724 C4845 C4851 C5074 C5075 C5076 C5090 C5091 C5105 C5115 C5116 C5117 C5144 C5184 C5223 C5265 C5294 C5335 C5336 C5369 C5441 C5514 C5515 C6423 C6430 C6437 C6439 C6445 C6458 C6571 C6575 C6579 C6602 C6614 C6615 P5144 P5184 P5223 P5294 P5335 2 4 2 MP C3695 C3697 C3747 C3748 C4492 C4501 C4517 C4518 C4531 C4610 C4643 C4700 C4724 C4845 C4851 C5074 C5075 C5076 C5090 C5091 C5105 C5115 C5116 C5117 C5144 C5184 C5223 C5265 C5294 C5335 C5336 C5369 C5441 C5514 C5515 C6423 C6430 C6437 C6439 C6445 C6458 C6571 C6575 C6579 C6602 C6614 C6615 P3697 P3748 P4517 P4531 P4643 P4724 P4845 P5075 P5091 P5116 P5265 P5336 P5369 P5515 P6423 P6439 P6571 P6579 P6614 2 5 2 Injection 40 mg in 0.8 mL pre‑filled syringe, 6 Injection Humira VE MP C3695 C3747 C5074 C5076 C5090 C5115 C5117 C6575 C6602 C6615 1 0 1 Injection 40 mg in 0.8 mL pre‑filled pen, 6 Injection Humira VE MP C3695 C3747 C5074 C5076 C5090 C5115 C5117 C6575 C6602 C6615 1 0 1 Adapalene with benzoyl peroxide Gel 1 mg‑25 mg per g, 30 g Application Epiduo GA MP C4898 C4961 P4961 1 1 1 MP C4898 C4961 P4898 1 3 1 NP C4898 1 3 1 Adefovir Tablet containing adefovir dipivoxil 10 mg Oral APO-Adefovir TX MP C4490 C4510 60 5 30 D(100) Hepsera GI MP C4490 C4510 60 5 30 D(100) Adrenaline Injection 1 mg (as acid tartrate) in 1 mL (1 in 1,000) Injection Link Medical Products Pty Ltd LM PDP 5 0 5 MP NP 5 1 5 I.M. injection 150 micrograms in 0.3 mL single dose syringe auto‑injector (EpiPen Jr.) Injection EpiPen Jr. AL MP NP C4909 C4946 C4947 1 0 1 I.M. injection 150 micrograms in 0.3 mL single dose syringe auto‑injector (Anapen Junior) Injection Anapen Junior LM MP NP C4909 C4946 C4947 1 0 1 I.M. injection 300 micrograms in 0.3 mL single dose syringe auto‑injector (EpiPen) Injection EpiPen AL MP NP C4909 C4946 C4947 1 0 1 I.M. injection 300 micrograms in 0.3 mL single dose syringe auto‑injector (Anapen) Injection Anapen LM MP NP C4909 C4946 C4947 1 0 1 Aflibercept Solution for intravitreal injection 4 mg in 100 microlitres (40 mg per mL) Injection Eylea BN MP C4154 C5453 C5521 C6518 C6567 C6574 C6594 C6599 P4154 P5521 P6567 P6574 P6594 P6599 1 2 1 MP C4154 C5453 C5521 C6518 C6567 C6574 C6594 C6599 P5453 P6518 1 5 1 Albendazole Tablet 200 mg Oral Zentel AS MP NP C5680 C5712 C5797 C5817 P5712 P5797 P5817 6 0 6 MP NP C5680 C5712 C5797 C5817 P5680 6 1 6 Tablet 400 mg Oral Eskazole AS MP C5607 60 2 60 Alemtuzumab Solution concentrate for I.V. infusion 12 mg in 1.2 mL Injection Lemtrada GZ MP C4829 C4834 C4838 C4850 P4829 P4850 3 0 1 D(100) MP C4829 C4834 C4838 C4850 P4834 P4838 5 0 1 D(100) Alendronic Acid Tablet 70 mg (as alendronate sodium) Oral Alendrobell 70mg GQ MP NP C6310 C6323 C6327 4 5 4 Alendronate AN EA MP NP C6310 C6323 C6327 4 5 4 Alendronate Sandoz SZ MP NP C6310 C6323 C6327 4 5 4 Alendro Once Weekly RW MP NP C6310 C6323 C6327 4 5 4 APO‑Alendronate TX MP NP C6310 C6323 C6327 4 5 4 Densate 70 DO MP NP C6310 C6323 C6327 4 5 4 Fonat AL MP NP C6310 C6323 C6327 4 5 4 Alendronic acid with colecalciferol Tablet 70 mg (as alendronate sodium) with 70 micrograms colecalciferol Oral a Alendrobell plus D3 GQ MP NP C6307 C6315 C6320 4 5 4 a Alendronate D3 70 mg/70 microgram EA MP NP C6307 C6315 C6320 4 5 4 a Alendronate plus D3-DRLA RZ MP NP C6307 C6315 C6320 4 5 4 a Alendronate Plus D3 Sandoz SZ MP NP C6307 C6315 C6320 4 5 4 a APO-Alendronate Plus D3 70 mg/70 mcg TX MP NP C6307 C6315 C6320 4 5 4 a Chem mart Alendronate Plus D3 70 mg/70 mcg CH MP NP C6307 C6315 C6320 4 5 4 a FonatPlus AF MP NP C6307 C6315 C6320 4 5 4 a Fosamax Plus MK MP NP C6307 C6315 C6320 4 5 4 a Terry White Chemists Alendronate Plus D3 70 mg/70 mcg TW MP NP C6307 C6315 C6320 4 5 4 Tablet 70 mg (as alendronate sodium) with 140 micrograms colecalciferol Oral a Alendrobell plus D3 GQ MP NP C6306 C6319 C6325 4 5 4 a Alendronate D3 70 mg/140 microgram EA MP NP C6306 C6319 C6325 4 5 4 a Alendronate plus D3-DRLA RZ MP NP C6306 C6319 C6325 4 5 4 a Alendronate Plus D3 Sandoz SZ MP NP C6306 C6319 C6325 4 5 4 a APO-Alendronate Plus D3 70 mg/140 mcg TX MP NP C6306 C6319 C6325 4 5 4 a Chem mart Alendronate Plus D3 70 mg/140 mcg CH MP NP C6306 C6319 C6325 4 5 4 a Dronalen Plus AL MP NP C6306 C6319 C6325 4 5 4 a FonatPlus AF MP NP C6306 C6319 C6325 4 5 4 a Fosamax Plus 70 mg/140 mcg MK MP NP C6306 C6319 C6325 4 5 4 a Terry White Chemists Alendronate Plus D3 70 mg/140 mcg TW MP NP C6306 C6319 C6325 4 5 4 Alendronic acid with colecalciferol and calcium Pack containing 4 tablets containing alendronic acid 70 mg (as alendronate sodium) with 140 micrograms colecalciferol and 48 tablets calcium 500 mg (as carbonate) Oral Alendronate Plus D3 and Calcium Sandoz SZ MP NP C6306 C6319 C6325 1 5 1 Alendronate Plus D3 Calcium Actavis EA MP NP C6306 C6319 C6325 1 5 1 Dronalen Plus D‑Cal AL MP NP C6306 C6319 C6325 1 5 1 Fosamax Plus D‑Cal MK MP NP C6306 C6319 C6325 1 5 1 ReddyMax Plus D-Cal RZ MP NP C6306 C6319 C6325 1 5 1 Allopurinol Tablet 100 mg Oral a Allopurinol Sandoz SZ MP NP 200 2 200 a Allosig RF MP NP 200 2 200 a APO-Allopurinol TX MP NP 200 2 200 a Chem mart Allopurinol CH MP NP 200 2 200 a Progout 100 AF MP NP 200 2 100 MP NP 200 2 200 a Terry White Chemists Allopurinol TW MP NP 200 2 200 a Zyloprim RW MP NP 200 2 200 Tablet 300 mg Oral Allopurinol Sandoz SZ MP NP 60 2 60 Allosig RF MP NP 60 2 60 APO-Allopurinol TX MP NP 60 2 60 Chem mart Allopurinol CH MP NP 60 2 60 Progout 300 AF MP NP 60 2 60 Terry White Chemists Allopurinol TW MP NP 60 2 60 Zyloprim RW MP NP 60 2 60 Alogliptin Tablet 6.25 mg (as benzoate) Oral Nesina TK MP NP C4349 28 5 28 Tablet 12.5 mg (as benzoate) Oral Nesina TK MP NP C4349 28 5 28 Tablet 25 mg (as benzoate) Oral Nesina TK MP NP C4349 28 5 28 Alogliptin with metformin Tablet containing 12.5 mg alogliptin (as benzoate) and 500 mg metformin hydrochloride Oral Nesina Met 12.5/500 TK MP NP C4423 C4427 56 5 56 Tablet containing 12.5 mg alogliptin (as benzoate) and 850 mg metformin hydrochloride Oral Nesina Met 12.5/850 TK MP NP C4423 C4427 56 5 56 Tablet containing 12.5 mg alogliptin (as benzoate) and 1 g metformin hydrochloride Oral Nesina Met 12.5/1000 TK MP NP C4423 C4427 56 5 56 Alprazolam Tablet 250 micrograms Oral Alprax 0.25 QA MP NP C5608 50 0 50 Kalma 0.25 AF MP NP C5608 50 0 50 Tablet 500 micrograms Oral Alprax 0.5 QA MP NP C5608 50 0 50 Kalma 0.5 AF MP NP C5608 50 0 50 Tablet 1 mg Oral Alprax 1 QA MP NP C5608 50 2 50 GenRx Alprazolam GX MP NP C5608 50 2 50 Kalma 1 AF MP NP C5608 50 2 50 Tablet 2 mg Oral Alprax 2 QA MP NP C5608 50 2 50 GenRx Alprazolam GX MP NP C5608 50 2 50 Kalma 2 AF MP NP C5608 50 2 50 Amantadine Capsule containing amantadine hydrochloride 100 mg Oral Symmetrel 100 NV MP NP C5132 100 5 100 Ambrisentan Tablet 5 mg Oral Volibris GK MP See Note 3 See Note 3 See Note 3 See
Note 330 D(100) Tablet 10 mg Oral Volibris GK MP See Note 3 See Note 3 See Note 3 See
Note 330 D(100) Amino acid formula with carbohydrate, vitamins, minerals and trace elements without phenylalanine Sachets containing oral powder 20 g, 30 (PKU Go) Oral PKU Go OH MP NP C4295 4 5 1 Amino acid formula with fat, carbohydrate, vitamins, minerals and long chain polyunsaturated fatty acids without phenylalanine and supplemented with docosahexanoic acid Oral liquid 500 mL, 20 (PKU Baby) Oral PKU Baby OH MP NP C4295 2 5 1 Amino acid formula with fat, carbohydrate, vitamins, minerals, and trace elements, without methionine and supplemented with docosahexanoic acid Oral liquid 125 mL, 36 (HCU Anamix junior LQ) Oral HCU Anamix junior LQ SB MP NP C5534 4 5 1 Amino acid formula with fat, carbohydrate, vitamins, minerals and trace elements without phenylalanine Bottles containing oral powder 34 g, 30 (PKU Easy Shake & Go) Oral PKU Easy Shake & Go OH MP NP C5970 4 5 1 Amino acid formula with fat, carbohydrate, vitamins, minerals and trace elements without phenylalanine and tyrosine Bottles containing oral powder 34 g, 30 (TYR Easy Shake & Go) Oral TYR Easy Shake & Go OH MP NP C5533 4 5 1 Amino acid formula with fat, carbohydrate, vitamins, minerals and trace elements without phenylalanine and tyrosine, and supplemented with docosahexanoic acid Oral liquid 125 mL, 36 (TYR Anamix junior LQ) Oral TYR Anamix junior LQ SB MP NP C5533 4 5 1 Amino acid formula with fat, carbohydrate, vitamins, minerals, trace elements and medium chain tryglycerides Oral powder 400 g (Alfamino Junior) Oral Alfamino Junior NT MP NP C4305 C4312 C4323 C4330 C4337 C4338 C4339 C4345 C4352 C4415 C5945 C5974 8 5 1 Amino acid formula with fat, carbohydrate, without phenylalanine Tablet: modified release, 70.8 g protein per 100 g, 110 g (PKU Easy Microtabs) Oral PKU Easy Microtabs OH MP NP C5970 5 5 1 Amino acid formula without phenylalanine Capsules 500 mg, 200 (Phlexy‑10) Oral Phlexy‑10 SB MP NP C4295 16 5 1 Tablets 1 g, 75 (Phlexy‑10) Oral Phlexy‑10 SB MP NP C4295 24 5 1 Sachets containing oral powder 20 g, 30 (Phlexy‑10 Drink Mix) Oral Phlexy‑10 Drink Mix SB MP NP C4295 7 5 1 Amino acid formula without valine, leucine and isoleucine Sachets containing oral powder 6 g, 30 (MSUD amino5) Oral MSUD amino5 VF MP NP C5571 12 5 1 Amino acid formula with vitamins, minerals and long chain polyunsaturated fatty acids without phenylalanine Oral powder 400 g (PKU Anamix infant) Oral PKU Anamix infant SB MP NP C4295 8 5 1 Amino acid formula with vitamins and minerals without lysine and low in tryptophan Sachets containing oral powder 18 g, 30 (GA1 Anamix Junior) Oral GA1 Anamix Junior NU MP NP C6007 8 5 1 Sachets containing oral powder 24 g, 30 (GA gel) Oral GA gel VF MP NP C5323 4 5 1 Oral powder 400 g (GA1 Anamix infant) Oral GA1 Anamix infant SB MP NP C5323 8 5 1 Oral powder 500 g (XLYS, LOW TRY Maxamaid) Oral XLYS, LOW TRY Maxamaid SB MP NP C5323 8 5 1 Oral powder 500 g (XLYS, LOW TRY Maxamum) Oral XLYS, LOW TRY Maxamum SB MP NP C5323 9 5 1 Sachets containing oral powder 25 g, 30 (GA express 15) Oral GA express 15 VF MP NP C5323 4 5 1 Amino acid formula with vitamins and minerals without methionine Oral powder 400 g (HCU Anamix infant) Oral HCU Anamix infant SB MP NP C5559 8 5 1 Sachets containing oral powder 24 g, 30 (HCU gel) Oral HCU gel VF MP NP C5534 4 5 1 Sachets containing oral powder 25 g, 30 (HCU express 15) Oral HCU express 15 VF MP NP C5534 4 5 1 Sachets containing oral powder 36 g, 30 (HCU Anamix Junior) Oral HCU Anamix Junior NU MP NP C6038 4 5 1 Oral powder 500 g (XMET Maxamaid) Oral XMET Maxamaid SB MP NP C5534 8 5 1 Oral powder 500 g (XMET Maxamum) Oral XMET Maxamum SB MP NP C5534 8 5 1 Oral liquid 87 mL, 30 (HCU cooler 10) Oral HCU cooler 10 VF MP NP C5534 4 5 1
Oral liquid 125 mL, 30 (HCU Lophlex LQ 20) Oral HCU Lophlex LQ 20 SB MP NP C5534 3 5 1 Oral liquid 130 mL, 30 (HCU cooler 15) Oral HCU cooler 15 VF MP NP C5534 4 5 1 Oral liquid 174 mL, 30 (HCU cooler 20) Oral HCU cooler 20 VF MP NP C5534 4 5 1 Amino acid formula with vitamins and minerals without methionine, threonine and valine and low in isoleucine Sachets containing oral powder 18 g, 30 (MMA/PA Anamix Junior) Oral MMA/PA Anamix Junior NU MP NP C5986 C6055 8 5 1 Sachets containing oral powder 25 g, 30 (MMA/PA express 15) Oral MMA/PA express 15 VF MP NP C5542 C5560 4 5 1 Sachets containing oral powder 24 g, 30 (MMA/PA gel) Oral MMA/PA gel VF MP NP C5542 C5560 4 5 1 Oral powder 400 g (MMA/PA Anamix infant) Oral MMA/PA Anamix infant SB MP NP C5542 C5560 8 5 1 Oral powder 500 g (XMTVI Maxamaid) Oral XMTVI Maxamaid SB MP NP C5542 C5560 8 5 1 Oral powder 500 g (XMTVI Maxamum) Oral XMTVI Maxamum SB MP NP C5542 C5560 8 5 1 Oral liquid 130 mL, 30 (MMA/PA cooler 15) Oral MMA/PA cooler 15 VF MP NP C5542 C5560 4 5 1 Amino acid formula with vitamins and minerals without phenylalanine Sachets containing oral powder 18.2 g, 60 (add‑ins) Oral add‑ins SB MP NP C4295 3 5 1 Sachets containing oral powder 24 g, 30 (PKU gel) Oral PKU gel VF MP NP C4295 4 5 1 Sachets containing oral powder 25 g, 30 (PKU express 15) Oral PKU express 15 VF MP NP C4295 4 5 1 Sachets containing oral powder 27.8 g, 30 (Lophlex) Oral Lophlex SB MP NP C4295 3 5 1 Sachets containing oral powder 34 g, 30 (PKU express 20) Oral PKU express 20 VF MP NP C4295 4 5 1 Sachets containing oral powder 36 g, 30 (PKU Anamix Junior) Oral PKU Anamix Junior SB MP NP C4964 4 5 1 Sachets containing oral powder 50 g, 30 (XP Maxamum) Oral XP Maxamum SB MP NP C4295 3 5 1 Oral gel 85 g, 30 (PKU squeezie) Oral PKU squeezie VF MP NP C4295 4 5 1 Oral powder 500 g (XP Maxamaid) Oral XP Maxamaid SB MP NP C4295 8 5 1 Oral powder 500 g (XP Maxamum) Oral XP Maxamum SB MP NP C4295 8 5 1 Oral liquid 250 mL (Easiphen) Oral Easiphen SB MP NP C4295 90 5 18 Oral liquid 62.5 mL, 60 (PKU Lophlex LQ 10) Oral PKU Lophlex LQ 10 SB MP NP C4295 2 5 1 Oral liquid 87 mL, 30 (PKU Cooler 10) Oral PKU Cooler 10 VF MP NP C4295 4 5 1 Oral liquid 125 mL, 30 (PKU Lophlex LQ 20) Oral PKU Lophlex LQ 20 SB MP NP C4295 3 5 1 Oral liquid 125 mL, 36 (PKU Anamix Junior LQ) Oral PKU Anamix Junior LQ SB MP NP C4295 4 5 1 Oral liquid 130 mL, 30 (PKU Air 15) Oral PKU Air 15 VF MP NP C4295 4 5 1 Oral liquid 130 mL, 30 (PKU Cooler 15) Oral PKU Cooler 15 VF MP NP C4295 4 5 1 Oral liquid 174 mL, 30 (PKU Air 20) Oral PKU Air 20 VF MP NP C4295 4 5 1 Oral liquid 174 mL, 30 (PKU Cooler 20) Oral PKU Cooler 20 VF MP NP C4295 4 5 1 Oral semi-solid 109 g, 36 (PKU Lophlex Sensation 20) Oral PKU Lophlex Sensation 20 SB MP NP C4295 3 5 1 Amino acid formula with vitamins and minerals without phenylalanine and tyrosine Sachets containing oral powder 24 g, 30 (TYR gel) Oral TYR gel VF MP NP C5533 4 5 1 Sachets containing oral powder 25 g, 30 (TYR express 15) Oral TYR express 15 VF MP NP C5533 4 5 1 Sachets containing oral powder 36 g, 30 (TYR Anamix Junior) Oral TYR Anamix Junior SB MP NP C4923 4 5 1 Oral powder 400 g (TYR Anamix infant) Oral TYR Anamix infant SB MP NP C5533 8 5 1 Oral powder 500 g (XPhen, Tyr Maxamaid) Oral XPhen, Tyr Maxamaid SB MP NP C5533 8 5 1 Oral powder 500 g (XPhen, Tyr Maxamum) Oral XPhen, Tyr Maxamum SB MP NP C5533 8 5 1 Oral liquid 87 mL, 30 (TYR cooler 10) Oral TYR cooler 10 VF MP NP C5533 4 5 1 Oral liquid 125 mL, 30 (TYR Lophlex LQ 20) Oral TYR Lophlex LQ 20 SB MP NP C5533 3 5 1 Oral liquid 130 mL, 30 (TYR cooler 15) Oral TYR cooler 15 VF MP NP C5533 4 5 1 Oral liquid 174 mL, 30 (TYR cooler 20) Oral TYR cooler 20 VF MP NP C5533 4 5 1 Amino acid formula with vitamins and minerals without valine, leucine and isoleucine Sachets containing oral powder 24 g, 30 (MSUD gel) Oral MSUD gel VF MP NP C5571 4 5 1 Sachets containing oral powder 25 g, 30 (MSUD express 15) Oral MSUD express 15 VF MP NP C5571 4 5 1 Sachets containing oral powder 34 g, 30 (MSUD express 20) Oral MSUD express 20 VF MP NP C5571 4 5 1 Sachets containing oral powder 36 g, 30 (MSUD Anamix Junior) Oral MSUD Anamix Junior SB MP NP C4954 4 5 1 Oral powder 400 g (MSUD Anamix infant) Oral MSUD Anamix infant SB MP NP C5571 8 5 1 Oral powder 500 g (MSUD AID III) Oral MSUD AID III SB MP NP C5571 4 5 1 Oral powder 500 g (MSUD Maxamaid) Oral MSUD Maxamaid SB MP NP C5571 8 5 1 Oral powder 500 g (MSUD Maxamum) Oral MSUD Maxamum SB MP NP C5571 8 5 1 Oral liquid 87 mL, 30 (MSUD cooler 10) Oral MSUD cooler 10 VF MP NP C5571 4 5 1 Oral liquid 125 mL, 30 (MSUD Lophlex LQ 20) Oral MSUD Lophlex LQ 20 SB MP NP C5571 3 5 1 Oral liquid 130 mL, 30 (MSUD cooler 15) Oral MSUD cooler 15 VF MP NP C5571 4 5 1 Oral liquid 174 mL, 30 (MSUD cooler 20) Oral MSUD cooler 20 VF MP NP C5571 4 5 1 Amino acid formula with vitamins and minerals without valine, leucine and isoleucine with fat, carbohydrate and trace elements and supplemented with docosahexanoic acid Oral liquid 125 mL, 36 (MSUD Anamix Junior LQ) Oral MSUD Anamix Junior LQ SB MP NP C5571 4 5 1 Amino acids—synthetic, formula Oral powder 400 g (EleCare) Oral EleCare AB MP NP C4305 C4312 C4323 C4330 C4337 C4338 C4339 C4345 C4352 C4368 C4414 C4415 P4305 P4312 P4323 P4330 P4337 P4338 P4339 P4345 P4352 P4415 8 5 1 MP NP C4305 C4312 C4323 C4330 C4337 C4338 C4339 C4345 C4352 C4368 C4414 C4415 P4368 P4414 12 5 1 Oral powder 400 g (Neocate Advance) Oral Neocate Advance SB MP NP C4305 C4312 C4323 C4330 C4337 C4338 C4339 C4345 C4352 C4415 8 5 1 Oral powder 400 g (Neocate Advance Vanilla) Oral Neocate Advance Vanilla SB MP NP C4305 C4312 C4323 C4330 C4337 C4338 C4339 C4345 C4352 C4368 C4414 C4415 P4305 P4312 P4323 P4330 P4337 P4338 P4339 P4345 P4352 P4415 8 5 1 MP NP C4305 C4312 C4323 C4330 C4337 C4338 C4339 C4345 C4352 C4368 C4414 C4415 P4368 P4414 12 5 1 Amino acid synthetic formula supplemented with long chain polyunsaturated fatty acids Oral powder 400 g (EleCare LCP) Oral EleCare LCP AB MP NP C4305 C4312 C4323 C4330 C4337 C4338 C4339 C4345 C4352 C4415 8 5 1 Oral powder 400 g (Neocate LCP) Oral Neocate LCP SB MP NP C4305 C4312 C4323 C4330 C4337 C4338 C4339 C4345 C4352 C4415 8 5 1 Amino acid synthetic formula supplemented with long chain polyunsaturated fatty acids and medium chain triglycerides Oral powder 400 g (Alfamino) Oral Alfamino NT MP NP C4305 C4312 C4323 C4330 C4337 C4338 C4339 C4345 C4352 C4415 C5945 C5974 8 5 1 Oral powder 400 g (Neocate Gold) Oral Neocate Gold SB MP NP C4305 C4312 C4323 C4330 C4337 C4338 C4339 C4345 C4352 C4368 C4414 C4415 P4305 P4312 P4323 P4330 P4337 P4338 P4339 P4345 P4352 P4415 8 5 1 C4305 C4312 C4323 C4330 C4337 C4338 C4339 C4345 C4352 C4368 C4414 C4415 P4368 P4414 12 5 1 Amiodarone Tablet containing amiodarone hydrochloride 100 mg Oral Aratac 100 AF MP NP C5665 30 5 30 Cordarone X 100 SW MP NP C5665 30 5 30 Tablet containing amiodarone hydrochloride 200 mg Oral Amiodarone Sandoz SZ MP NP C5665 30 5 30 Aratac 200 AF MP NP C5665 30 5 30 Chem mart Amiodarone CH MP NP C5665 30 5 30 Cordarone X 200 SW MP NP C5665 30 5 30 GenRx Amiodarone GX MP NP C5665 30 5 30 Rithmik 200 RW MP NP C5665 30 5 30 Terry White Chemists Amiodarone TW MP NP C5665 30 5 30 Amisulpride Tablet 100 mg Oral Amisulpride 100 Winthrop WA MP NP C4246 30 5 30 Amisulpride Sandoz SZ MP NP C4246 30 5 30 APO‑Amisulpride TX MP NP C4246 30 5 30 Solian 100 SW MP NP C4246 30 5 30 Sulprix AF MP NP C4246 30 5 30 Tablet 200 mg Oral Amisulpride 200 Winthrop WA MP NP C4246 60 5 60 Amisulpride Sandoz SZ MP NP C4246 60 5 60 APO‑Amisulpride TX MP NP C4246 60 5 60 Solian 200 SW MP NP C4246 60 5 60 Sulprix AF MP NP C4246 60 5 60 Tablet 400 mg Oral Amipride 400 RW MP NP C4246 60 5 60 Amisulpride 400 Winthrop WA MP NP C4246 60 5 60 Amisulpride Sandoz SZ MP NP C4246 60 5 60 APO‑Amisulpride TX MP NP C4246 60 5 60 Solian 400 SW MP NP C4246 60 5 60 Sulprix AF MP NP C4246 60 5 60 Oral solution 100 mg per mL, 60 mL Oral Solian Solution SW MP NP C4246 2 5 1 Amitriptyline Tablet containing amitriptyline hydrochloride 10 mg Oral a Amitriptyline Alphapharm 10 AL MP NP 50 2 50 a APO-Amitriptyline 10 TX MP NP 50 2 50 a Chem mart Amitriptyline CH MP NP 50 2 50 a Endep 10 AF MP NP 50 2 50 a ENTRIP RW MP NP 50 2 50 a Terry White Chemists Amitriptyline TW MP NP 50 2 50 Tablet containing amitriptyline hydrochloride 25 mg Oral a Amitriptyline Alphapharm 25 AL MP NP 50 2 50 a APO-Amitriptyline 25 TX MP NP 50 2 50 a Chem mart Amitriptyline CH MP NP 50 2 50 a Endep 25 AF MP NP 50 2 50 a ENTRIP RW MP NP 50 2 50 a Terry White Chemists Amitriptyline TW MP NP 50 2 50 Tablet containing amitriptyline hydrochloride 50 mg Oral a Amitriptyline Alphapharm 50 AL MP NP 50 2 50 a APO-Amitriptyline 50 TX MP NP 50 2 50 a Chem mart Amitriptyline CH MP NP 50 2 50 a Endep 50 AF MP NP 50 2 50 a ENTRIP RW MP NP 50 2 50 a Terry White Chemists Amitriptyline TW MP NP 50 2 50 Amlodipine Tablet 5 mg (as besylate) Oral a Amlo 5 RW MP NP 30 5 30 a Amlodipine AN EA MP NP 30 5 30 a Amlodipine GH GQ MP NP 30 5 30 a Amlodipine Sandoz SZ MP NP 30 5 30 a APO‑Amlodipine TX MP NP 30 5 30 a Auro‑Amlodipine 5 DO MP NP 30 5 30 a Blooms the Chemist Amlodipine IB MP NP 30 5 30 a Chem mart Amlodipine CH MP NP 30 5 30 a Nordip AF MP NP 30 5 30 a Norvapine ED MP NP 30 5 30 a Norvasc PF MP NP 30 5 30 a Ozlodip RA MP NP 30 5 30 a Pharmacor Amlodipine CR MP NP 30 5 30 a Terry White Chemists Amlodipine TW MP NP 30 5 30 Tablet 10 mg (as besylate) Oral a Amlo 10 RW MP NP 30 5 30 a Amlodipine AN EA MP NP 30 5 30 a Amlodipine GH GQ MP NP 30 5 30 a Amlodipine Sandoz SZ MP NP 30 5 30 a APO‑Amlodipine TX MP NP 30 5 30 a Auro‑Amlodipine 10 DO MP NP 30 5 30 a Blooms the Chemist Amlodipine IB MP NP 30 5 30 a Chem mart Amlodipine CH MP NP 30 5 30 a Nordip AF MP NP 30 5 30 a Norvapine ED MP NP 30 5 30 a Norvasc PF MP NP 30 5 30 a Ozlodip RA MP NP 30 5 30 a Pharmacor Amlodipine CR MP NP 30 5 30 a Terry White Chemists Amlodipine TW MP NP 30 5 30 Amlodipine with Atorvastatin Tablet 5 mg amlodipine (as besylate) with 10 mg atorvastatin (as calcium) Oral APO-Amlodipine/ Atorvastatin 5/10 TX MP NP C5619 C5694 C5750 C5751 C5787 C5788 30 5 30 Blooms the Chemist Amlodipine/ Atorvastatin 5/10 IB MP NP C5619 C5694 C5750 C5751 C5787 C5788 30 5 30 Cadivast 5/10 AF MP NP C5619 C5694 C5750 C5751 C5787 C5788 30 5 30 Caduet 5/10 PF MP NP C5619 C5694 C5750 C5751 C5787 C5788 30 5 30 Chem mart Amlodipine/ Atorvastatin 5/10 CH MP NP C5619 C5694 C5750 C5751 C5787 C5788 30 5 30 Terry White Chemists Amlodipine/ Atorvastatin 5/10 TW MP NP C5619 C5694 C5750 C5751 C5787 C5788 30 5 30 Tablet 5 mg amlodipine (as besylate) with 20 mg atorvastatin (as calcium) Oral APO-Amlodipine/ Atorvastatin 5/20 TX MP NP C5619 C5694 C5750 C5751 C5787 C5788 30 5 30 Blooms the Chemist Amlodipine/ Atorvastatin 5/20 IB MP NP C5619 C5694 C5750 C5751 C5787 C5788 30 5 30 Cadivast 5/20 AF MP NP C5619 C5694 C5750 C5751 C5787 C5788 30 5 30 Caduet 5/20 PF MP NP C5619 C5694 C5750 C5751 C5787 C5788 30 5 30 Chem mart Amlodipine/ Atorvastatin 5/20 CH MP NP C5619 C5694 C5750 C5751 C5787 C5788 30 5 30 Terry White Chemists Amlodipine/ Atorvastatin 5/20 TW MP NP C5619 C5694 C5750 C5751 C5787 C5788 30 5 30 Tablet 5 mg amlodipine (as besylate) with 40 mg atorvastatin (as calcium) Oral APO-Amlodipine/ Atorvastatin 5/40 TX MP NP C5619 C5694 C5750 C5751 C5787 C5788 30 5 30 Blooms the Chemist Amlodipine/ Atorvastatin 5/40 IB MP NP C5619 C5694 C5750 C5751 C5787 C5788 30 5 30 Cadivast 5/40 AF MP NP C5619 C5694 C5750 C5751 C5787 C5788 30 5 30 Caduet 5/40 PF MP NP C5619 C5694 C5750 C5751 C5787 C5788 30 5 30 Chem mart Amlodipine/ Atorvastatin 5/40 CH MP NP C5619 C5694 C5750 C5751 C5787 C5788 30 5 30 Terry White Chemists Amlodipine/ Atorvastatin 5/40 TW MP NP C5619 C5694 C5750 C5751 C5787 C5788 30 5 30 Tablet 5 mg amlodipine (as besylate) with 80 mg atorvastatin (as calcium) Oral APO-Amlodipine/ Atorvastatin 5/80 TX MP NP C5619 C5694 C5750 C5751 C5787 C5788 30 5 30 Blooms the Chemist Amlodipine/ Atorvastatin 5/80 IB MP NP C5619 C5694 C5750 C5751 C5787 C5788 30 5 30 Cadivast 5/80 AF MP NP C5619 C5694 C5750 C5751 C5787 C5788 30 5 30 Caduet 5/80 PF MP NP C5619 C5694 C5750 C5751 C5787 C5788 30 5 30 Chem mart Amlodipine/ Atorvastatin 5/80 CH MP NP C5619 C5694 C5750 C5751 C5787 C5788 30 5 30 Terry White Chemists Amlodipine/ Atorvastatin 5/80 TW MP NP C5619 C5694 C5750 C5751 C5787 C5788 30 5 30 Tablet 10 mg amlodipine (as besylate) with 10 mg atorvastatin (as calcium) Oral APO-Amlodipine/ Atorvastatin 10/10 TX MP NP C5619 C5694 C5750 C5751 C5787 C5788 30 5 30 Blooms the Chemist Amlodipine/ Atorvastatin 10/10 IB MP NP C5619 C5694 C5750 C5751 C5787 C5788 30 5 30 Cadivast 10/10 AF MP NP C5619 C5694 C5750 C5751 C5787 C5788 30 5 30 Caduet 10/10 PF MP NP C5619 C5694 C5750 C5751 C5787 C5788 30 5 30 Chem mart Amlodipine/ Atorvastatin 10/10 CH MP NP C5619 C5694 C5750 C5751 C5787 C5788 30 5 30 Terry White Chemists Amlodipine/ Atorvastatin 10/10 TW MP NP C5619 C5694 C5750 C5751 C5787 C5788 30 5 30 Tablet 10 mg amlodipine (as besylate) with 20 mg atorvastatin (as calcium) Oral APO-Amlodipine/ Atorvastatin 10/20 TX MP NP C5619 C5694 C5750 C5751 C5787 C5788 30 5 30 Blooms the Chemist Amlodipine/ Atorvastatin 10/20 IB MP NP C5619 C5694 C5750 C5751 C5787 C5788 30 5 30 Cadivast 10/20 AF MP NP C5619 C5694 C5750 C5751 C5787 C5788 30 5 30 Caduet 10/20 PF MP NP C5619 C5694 C5750 C5751 C5787 C5788 30 5 30 Chem mart Amlodipine/ Atorvastatin 10/20 CH MP NP C5619 C5694 C5750 C5751 C5787 C5788 30 5 30 Terry White Chemists Amlodipine/ Atorvastatin 10/20 TW MP NP C5619 C5694 C5750 C5751 C5787 C5788 30 5 30 Tablet 10 mg amlodipine (as besylate) with 40 mg atorvastatin (as calcium) Oral APO-Amlodipine/ Atorvastatin 10/40 TX MP NP C5619 C5694 C5750 C5751 C5787 C5788 30 5 30 Blooms the Chemist Amlodipine/ Atorvastatin 10/40 IB MP NP C5619 C5694 C5750 C5751 C5787 C5788 30 5 30 Cadivast 10/40 AF MP NP C5619 C5694 C5750 C5751 C5787 C5788 30 5 30 Caduet 10/40 PF MP NP C5619 C5694 C5750 C5751 C5787 C5788 30 5 30 Chem mart Amlodipine/ Atorvastatin 10/40 CH MP NP C5619 C5694 C5750 C5751 C5787 C5788 30 5 30 Terry White Chemists Amlodipine/ Atorvastatin 10/40 TW MP NP C5619 C5694 C5750 C5751 C5787 C5788 30 5 30 Tablet 10 mg amlodipine (as besylate) with 80 mg atorvastatin (as calcium) Oral APO-Amlodipine/ Atorvastatin 10/80 TX MP NP C5619 C5694 C5750 C5751 C5787 C5788 30 5 30 Blooms the Chemist Amlodipine/ Atorvastatin 10/80 IB MP NP C5619 C5694 C5750 C5751 C5787 C5788 30 5 30 Cadivast 10/80 AF MP NP C5619 C5694 C5750 C5751 C5787 C5788 30 5 30 Caduet 10/80 PF MP NP C5619 C5694 C5750 C5751 C5787 C5788 30 5 30 Chem mart Amlodipine/ Atorvastatin 10/80 CH MP NP C5619 C5694 C5750 C5751 C5787 C5788 30 5 30 Terry White Chemists Amlodipine/ Atorvastatin 10/80 TW MP NP C5619 C5694 C5750 C5751 C5787 C5788 30 5 30 Amlodipine with valsartan Tablet 5 mg (as besylate)‑80 mg Oral Exforge 5/80 NV MP NP C4373 28 5 28 Valsartan/ Amlodipine Sandoz 80/5 NM MP NP C4373 28 5 28 Tablet 5 mg (as besylate)‑160 mg Oral Exforge 5/160 NV MP NP C4373 28 5 28 Tablet 5 mg (as besylate)‑320 mg Oral Exforge 5/320 NV MP NP C4373 28 5 28 Tablet 10 mg (as besylate)‑160 mg Oral Exforge 10/160 NV MP NP C4373 28 5 28 Tablet 10 mg (as besylate)‑320 mg Oral Exforge 10/320 NV MP NP C4373 28 5 28 Amlodipine with valsartan and hydrochlorothiazide Tablet 5 mg (as besylate)‑160 mg‑12.5 mg Oral Exforge HCT 5/160/12.5 NV MP NP C4311 28 5 28 Valsartan/ Amlodipine/HCT Sandoz 160/5/12.5 NM MP NP C4311 28 5 28 Tablet 5 mg (as besylate)‑160 mg‑25 mg Oral Exforge HCT 5/160/25 NV MP NP C4311 28 5 28 Tablet 10 mg (as besylate)‑160 mg‑12.5 mg Oral Exforge HCT 10/160/12.5 NV MP NP C4311 28 5 28 Tablet 10 mg (as besylate)‑160 mg‑25 mg Oral Exforge HCT 10/160/25 NV MP NP C4311 28 5 28 Tablet 10 mg (as besylate)‑320 mg‑25 mg Oral Exforge HCT 10/320/25 NV MP NP C4311 28 5 28 Amoxycillin Tablet 1 g (as trihydrate) Oral Amoxycillin Sandoz BG MP NP C5843
14 1 14 Maxamox SZ MP NP C5843
14 1 14 Capsule 250 mg (as trihydrate) Oral Alphamox 250 AF PDP 20 0 20 Amoxil AS PDP 20 0 20 Amoxycillin AN EA PDP 20 0 20 Amoxycillin Ranbaxy RA PDP 20 0 20 Amoxycillin Sandoz SZ PDP 20 0 20 APO‑Amoxycillin TX PDP 20 0 20 Chem mart Amoxycillin CH PDP 20 0 20 Cilamox QA PDP 20 0 20 Terry White Chemists Amoxycillin TW PDP 20 0 20 Yomax 250 DO PDP 20 0 20 Alphamox 250 AF MP NP MW 20 1 20 Amoxil AS MP NP MW 20 1 20 Amoxycillin AN EA MP NP MW 20 1 20 Amoxycillin Ranbaxy RA MP NP MW 20 1 20 Amoxycillin Sandoz SZ MP NP MW 20 1 20 APO‑Amoxycillin TX MP NP MW 20 1 20 Chem mart Amoxycillin CH MP NP MW 20 1 20 Cilamox QA MP NP MW 20 1 20 Terry White Chemists Amoxycillin TW MP NP MW 20 1 20 Yomax 250 DO MP NP MW 20 1 20 Capsule 500 mg (as trihydrate) Oral Alphamox 500 AF PDP 20 0 20 Amoxil AS PDP 20 0 20 Amoxycillin AN EA PDP 20 0 20 Amoxycillin generichealth 500 GQ PDP 20 0 20 Amoxycillin Ranbaxy RA PDP 20 0 20 Amoxycillin Sandoz SZ PDP 20 0 20 APO‑Amoxycillin TX PDP 20 0 20 Chem mart Amoxycillin CH PDP 20 0 20 Cilamox QA PDP 20 0 20 Terry White Chemists Amoxycillin TW PDP 20 0 20 Yomax 500 DO PDP 20 0 20 Alphamox 500 AF MP NP MW 20 1 20 Amoxil AS MP NP MW 20 1 20 Amoxycillin AN EA MP NP MW 20 1 20 Amoxycillin generichealth 500 GQ MP NP MW 20 1 20 Amoxycillin Ranbaxy RA MP NP MW 20 1 20 Amoxycillin Sandoz SZ MP NP MW 20 1 20 APO‑Amoxycillin TX MP NP MW 20 1 20 Chem mart Amoxycillin CH MP NP MW 20 1 20 Cilamox QA MP NP MW 20 1 20 Terry White Chemists Amoxycillin TW MP NP MW 20 1 20 Yomax 500 DO MP NP MW 20 1 20 Powder for paediatric oral drops 100 mg (as trihydrate) per mL, 20 mL Oral Amoxil AS PDP 1 0 1 MP NP P5863 1 1 1 Powder for oral suspension 125 mg (as trihydrate) per 5 mL, 100 mL Oral Alphamox 125 AF PDP 1 0 1 Amoxil AS PDP 1 0 1 Amoxycillin Sandoz SZ PDP 1 0 1 APO-Amoxycillin TX PDP 1 0 1 Chem mart Amoxycillin CH PDP 1 0 1 Ranmoxy RA PDP 1 0 1 Terry White Chemists Amoxycillin TW PDP 1 0 1 Alphamox 125 AF MP NP 1 1 1 Amoxil AS MP NP 1 1 1 Amoxycillin Sandoz SZ MP NP 1 1 1 APO-Amoxycillin TX MP NP 1 1 1 Chem mart Amoxycillin CH MP NP 1 1 1 Ranmoxy RA MP NP 1 1 1 Terry White Chemists Amoxycillin TW MP NP 1 1 1 Powder for oral suspension 250 mg (as trihydrate) per 5 mL, 100 mL Oral Alphamox 250 AF PDP 1 0 1 Amoxil Forte AS PDP 1 0 1 Amoxycillin Sandoz SZ PDP 1 0 1 APO-Amoxycillin TX PDP 1 0 1 Chem mart Amoxycillin CH PDP 1 0 1 Cilamox QA PDP 1 0 1 Ranmoxy RA PDP 1 0 1 Terry White Chemists Amoxycillin TW PDP 1 0 1 Alphamox 250 AF MP NP 1 1 1 Amoxil Forte AS MP NP 1 1 1 Amoxycillin Sandoz SZ MP NP 1 1 1 APO-Amoxycillin TX PDP 1 1 1 Chem mart Amoxycillin CH MP NP 1 1 1 Cilamox QA MP NP 1 1 1 Ranmoxy RA MP NP 1 1 1 Terry White Chemists Amoxycillin TW MP NP 1 1 1 Powder for oral suspension 500 mg (as trihydrate) per 5 mL, 100 mL Oral Maxamox SZ PDP 1 0 1 Maxamox SZ MP NP 1 1 1 Amoxycillin with Clavulanic Acid Tablet containing 500 mg amoxycillin (as trihydrate) with 125 mg clavulanic acid (as potassium clavulanate) Oral a AlphaClav Duo AF PDP C5833 C5894 10 0 10 a Amoxyclav AN 500/125 EA PDP C5833 C5894 10 0 10 a APO‑Amoxycillin/ Clavulanic Acid 500/125 TX PDP C5833 C5894 10 0 10 a Augmentin Duo AS PDP C5833 C5894 10 0 10 a Curam Duo 500/125 SZ PDP C5833 C5894 10 0 10 a Moxiclav Duo 500/125 QA PDP C5833 C5894 10 0 10 a AlphaClav Duo AF MP NP MW C5832 C5893 10 1 10 a Amoxyclav AN 500/125 EA MP NP MW C5832 C5893 10 1 10 a APO‑Amoxycillin/ Clavulanic Acid 500/125 TX MP NP MW C5832 C5893 10 1 10 a Augmentin Duo AS MP NP MW C5832 C5893 10 1 10 a Curam Duo 500/125 SZ MP NP MW C5832 C5893 10 1 10 a Moxiclav Duo 500/125 QA MP NP MW C5832 C5893 10 1 10 Tablet containing 875 mg amoxycillin (as trihydrate) with 125 mg clavulanic acid (as potassium clavulanate) Oral a AlphaClav Duo Forte AF PDP C5833 C5894 10 0 10 a Amoxyclav AN 875/125 EA PDP C5833 C5894 10 0 10 a AmoxyClav GH 875/125 GQ PDP C5833 C5894 10 0 10 a AmoxyClav RBX 875/125 RA PDP C5833 C5894 10 0 10 a APO-Amoxycillin and Clavulanic Acid TX PDP C5833 C5894 10 0 10 a Augmentin Duo forte AS PDP C5833 C5894 10 0 10 a Chem mart Amoxycillin and Clavulanic Acid CH PDP C5833 C5894 10 0 10 a Clavam 875 mg/125 mg CR PDP C5833 C5894 10 0 10 a Curam Duo Forte 875/125 SZ PDP C5833 C5894 10 0 10 a Moxiclav Duo Forte 875/125 QA PDP C5833 C5894 10 0 10 a Terry White Chemists Amoxycillin and Clavulanic Acid TW PDP C5833 C5894 10 0 10 a AlphaClav Duo Forte AF MP NP MW C5832 C5893 10 1 10 a Amoxyclav AN 875/125 EA MP NP C5832 C5893 10 1 10 a AmoxyClav GH 875/125 GQ MP NP C5832 C5893 10 1 10 a AmoxyClav RBX 875/125 RA MP NP C5832 C5893 10 1 10 a APO-Amoxycillin and Clavulanic Acid TX MP NP C5832 C5893 10 1 10 a Augmentin Duo forte AS MP NP C5832 C5893 10 1 10 a Chem mart Amoxycillin and Clavulanic Acid CH MP NP C5832 C5893 10 1 10 a Clavam 875 mg/125 mg CR MP NP C5832 C5893 10 1 10 a Curam Duo Forte 875/125 SZ MP NP C5832 C5893 10 1 10 a Moxiclav Duo Forte 875/125 QA MP NP C5832 C5893 10 1 10 a Terry White Chemists Amoxycillin and Clavulanic Acid TW MP NP C5832 C5893 10 1 10 Powder for oral suspension containing 125 mg amoxycillin (as trihydrate) with 31.25 mg clavulanic acid (as potassium clavulanate) per 5 mL, 75 mL Oral APO-Amoxycillin and Clavulanic Acid 125/31.25 TX PDP C5833 C5894 1 0 1 Augmentin AS PDP C5833 C5894 1 0 1 Curam SZ PDP C5833 C5894 1 0 1 APO-Amoxycillin and Clavulanic Acid 125/31.25 TX MP NP C5832 C5893 1 1 1 Augmentin AS MP NP C5832 C5893 1 1 1 Curam SZ MP NP C5832 C5893 1 1 1 Powder for oral suspension containing 400 mg amoxycillin (as trihydrate) with 57 mg clavulanic acid (as potassium clavulanate) per 5 mL, 60 mL Oral APO-Amoxycillin and Clavulanic Acid 400/57 TX PDP C5833 C5894 1 0 1 Augmentin Duo 400 AS PDP C5833 C5894 1 0 1 Curam Duo SZ PDP C5833 C5894 1 0 1 APO-Amoxycillin and Clavulanic Acid 400/57 TX MP NP C5832 C5893 1 1 1 Augmentin Duo 400 AS MP NP C5832 C5893 1 1 1 Curam Duo SZ MP NP C5832 C5893 1 1 1 Amphotericin Lozenge 10 mg Oral Fungilin QA PDP 20 0 20 MP NP 20 1 20 Ampicillin Powder for injection 500 mg (as sodium) Injection Austrapen AL PDP 5 0 5 MP NP 5 1 5 Powder for injection 1 g (as sodium) Injection Ampicyn AF PDP 5 0 5 Austrapen AL PDP 5 0 5 Ampicyn AF MP NP 5 1 5 Austrapen AL MP NP 5 1 5 Amylopectin, modified long chain Sachets containing oral powder 60 g, 30 (Glycosade) Oral Glycosade VF MP NP C5561 4 5 1 Anakinra Injection 100 mg in 0.67 mL single use pre-filled syringe Injection Kineret FK MP C5450 28 5 28 D(100) Anastrozole Tablet 1 mg Oral Anastrol QA MP NP C5464 30 5 30 Anastrozole AN EA MP NP C5464 30 5 30 Anastrozole FBM FO MP NP C5464 30 5 30 Anastrozole GH GQ MP NP C5464 30 5 30 Anastrozole RBX RA MP NP C5464 30 5 30 Anastrozole Sandoz SZ MP NP C5464 30 5 30 APO‑Anastrozole TX MP NP C5464 30 5 30 Arianna AF MP NP C5464 30 5 30 Arimidex AP MP NP C5464 30 5 30 Azastrole ER MP NP C5464 30 5 30 Chem mart Anastrozole CH MP NP C5464 30 5 30 Terry White Chemists Anastrozole TW MP NP C5464 30 5 30 Apixaban Tablet 2.5 mg Oral Eliquis BQ MP NP C4132 C4269 C4359 C4381 C4382 C4402 C4409 P4359 P4381 20 0 20 MP NP C4132 C4269 C4359 C4381 C4382 C4402 C4409 P4382 P4409 30 0 30 MP NP C4132 C4269 C4359 C4381 C4382 C4402 C4409 P4402 60 0 60 MP NP C4132 C4269 C4359 C4381 C4382 C4402 C4409 P4132 P4269 60 5 60 Tablet 5 mg Oral Eliquis BQ MP NP C4098 C4099 C4269 C5083 C5098 P4098 P5098 28 0 28 MP NP C4098 C4099 C4269 C5083 C5098 P4099 P4269 P5083 60 5 60 Apomorphine Injection containing apomorphine hydrochloride 10 mg in 1 mL Injection Apomine HH MP C4833 C4860 360 5 5 D(100) Injection containing apomorphine hydrochloride 20 mg in 2 mL Injection Movapo TD MP C4833 C4860 360 5 5 D(100) Injection containing apomorphine hydrochloride 50 mg in 5 mL Injection Movapo TD MP C4833 C4860 180 5 5 D(100) Solution for subcutaneous infusion containing apomorphine hydrochloride 50 mg in 10 mL pre-filled syringe Injection Movapo PFS TD MP C4833 C4860 180 5 5 D(100) Apraclonidine Eye drops 5 mg (as hydrochloride) per mL, 10 mL Application to the eye Iopidine 0.5% AQ MP C4901 1 2 1 Aprepitant Capsule 165 mg Oral Emend MK MP NP C4211 C4215 C6370 C6444 1 5 1 MP C4216 C4223 C6383 C6464 1 5 1 C(100) Arachidonic acid and docosahexaenoic acid with carbohydrate Sachets of oral powder 4 g containing 200 mg arachidonic acid and 100 mg docosahexaenoic acid , 30 (keyomega) Oral keyomega VF MP NP C6141 4 5 1 Arginine with carbohydrate Sachets of oral powder 4 g containing 500 mg arginine, 30 (Arginine 500) Oral Arginine 500 VF MP NP C4555 4 5 1 Sachets of oral powder 4 g containing 2 g arginine, 30 (Arginine 2000) Oral Arginine 2000 VF MP NP C4555 4 5 1 Sachets of oral powder 7.6 g containing 5 g arginine, 30 (Arginine 5000) Oral Arginine 5000 VF MP NP C4555 4 5 1 Aripiprazole Tablet 10 mg Oral a Abilify OS MP NP C4246 30 5 30 a Aripiprazole GH GQ MP NP C4246 30 5 30 a Aripiprazole Sandoz SZ MP NP C4246 30 5 30 Tablet 15 mg Oral a Abilify OS MP NP C4246 30 5 30 a Aripiprazole GH GQ MP NP C4246 30 5 30 a Aripiprazole Sandoz SZ MP NP C4246 30 5 30 Tablet 20 mg Oral a Abilify OS MP NP C4246 30 5 30 a Aripiprazole GH GQ MP NP C4246 30 5 30 a Aripiprazole Sandoz SZ MP NP C4246 30 5 30 Tablet 30 mg Oral a Abilify OS MP NP C4246 30 5 30 a Aripiprazole GH GQ MP NP C4246 30 5 30 a Aripiprazole Sandoz SZ MP NP C4246 30 5 30 Powder for injection 300 mg (as monohydrate) with diluent Injection Abilify Maintena LU MP NP C4246 1 5 1 Powder for injection 400 mg (as monohydrate) with diluent Injection Abilify Maintena LU MP NP C4246 1 5 1 Armodafinil Tablet 50 mg Oral Nuvigil TB MP C6503 C6547 60 5 30 Tablet 150 mg Oral Nuvigil TB MP C6503 C6547 30 5 30 Tablet 250 mg Oral Nuvigil TB MP C6503 C6547 30 5 30 Arsenic Injection concentrate containing arsenic trioxide 10 mg in 10 mL Injection Phenasen PL MP C4793 C5997 C6018 See Note 3 See
Note 310 D(100) Artemether with lumefantrine Tablet 20 mg‑120 mg Oral Riamet SZ MP C5999 24 0 24 Tablet (dispersible) 20 mg‑120 mg Oral Riamet 20mg/120mg Dispersible SZ MP C6036 18 0 18 Asenapine Sublingual wafer 5 mg (as maleate) Sublingual Saphris LU MP NP C4246 C5719 C5773 60 5 60 Sublingual wafer 10 mg (as maleate) Sublingual Saphris LU MP NP C4246 C5719 C5773 60 5 60 Aspirin Tablet 100 mg Oral Spren 100 OW MP NP C5884 112 1 112 Tablet, dispersible, 300 mg Oral Solprin RC PDP C5870 96 0 96 MP NP C5857 96 1 96 Atazanavir Capsule 150 mg (as sulfate) Oral Reyataz BQ MP C4454 C4512 120 5 60 D(100) Capsule 200 mg (as sulfate) Oral Reyataz BQ MP C4454 C4512 120 5 60 D(100) Capsule 300 mg (as sulfate) Oral Reyataz BQ MP C4454 C4512 60 5 30 D(100) Atazanavir with cobicistat Tablet containing 300 mg atazanavir and 150 mg cobicistat Oral Evotaz BQ MP C4454 C4512 60 5 30 D(100) Atenolol Tablet 50 mg Oral APO‑Atenolol TX MP NP 30 5 30 Atenolol AN EA MP NP 30 5 30 Atenolol‑GA ED MP NP 30 5 30 Atenolol GH GQ MP NP 30 5 30 Atenolol RBX RA MP NP 30 5 30 Atenolol Sandoz SZ MP NP 30 5 30 Chem mart Atenolol CH MP NP 30 5 30 Noten AF MP NP 30 5 30 Tenolten 50 DO MP NP 30 5 30 Tenormin AP MP NP 30 5 30 Tensig RW MP NP 30 5 30 Terry White Chemists Atenolol TW MP NP 30 5 30 Oral solution 50 mg in 10 mL, 300 mL Oral Atenolol‑AFT AE MP NP C4076 1 5 1 Atomoxetine Capsule 10 mg (as hydrochloride) Oral a APO-Atomoxetine TX MP C4578 C6279 56 5 28 a Atomoxetine Amneal EA MP C4578 C6279 56 5 28 a Strattera LY MP C4578 C6279 56 5 28 Capsule 18 mg (as hydrochloride) Oral a APO-Atomoxetine TX MP C4578 C6279 56 5 28 a Atomoxetine Amneal EA MP C4578 C6279 56 5 28 a Strattera LY MP C4578 C6279 56 5 28 Capsule 25 mg (as hydrochloride) Oral a APO-Atomoxetine TX MP C4578 C6279 56 5 28 a Atomoxetine Amneal EA MP C4578 C6279 56 5 28 a Strattera LY MP C4578 C6279 56 5 28 Capsule 40 mg (as hydrochloride) Oral a APO-Atomoxetine TX MP C4578 C6279 56 5 28 a Atomoxetine Amneal EA MP C4578 C6279 56 5 28 a Strattera LY MP C4578 C6279 56 5 28
Capsule 60 mg (as hydrochloride) Oral a APO-Atomoxetine TX MP C4578 C6279 56 5 28 a Atomoxetine Amneal EA MP C4578 C6279 56 5 28 a Strattera LY MP C4578 C6279 56 5 28 Capsule 80 mg (as hydrochloride) Oral a APO-Atomoxetine TX MP C4578 C6279 28 5 28 a Atomoxetine Amneal EA MP C4578 C6279 28 5 28 a Strattera LY MP C4578 C6279 28 5 28 Capsule 100 mg (as hydrochloride) Oral a APO-Atomoxetine TX MP C4578 C6279 28 5 28 a Atomoxetine Amneal EA MP C4578 C6279 28 5 28 a Strattera LY MP C4578 C6279 28 5 28 Atorvastatin Tablet 10 mg (as calcium) Oral a APO‑Atorvastatin TX MP C4238 C4263 P4263 30 5 30 NP C4263 30 5 30 a Atorvachol ED MP C4238 C4263 P4263 30 5 30 NP C4263 30 5 30 a Atorvastatin Amneal EF MP C4238 C4263 P4263 30 5 30 NP C4263 30 5 30 a Atorvastatin AN EA MP C4238 C4263 P4263 30 5 30 NP C4263 30 5 30 a Atorvastatin GH GQ MP C4238 C4263 P4263 30 5 30 NP C4263 30 5 30 a Atorvastatin Sandoz SZ MP C4238 C4263 P4263 30 5 30 NP C4263 30 5 30 a Atorvastatin SCP 10 RZ MP C4238 C4263 P4263 30 5 30 NP C4263 30 5 30 a Atorvastatin SZ HX MP C4238 C4263 P4263 30 5 30 NP C4263 30 5 30 a Blooms the Chemist Atorvastatin IB MP C4238 C4263 P4263 30 5 30 NP C4263 30 5 30 a Chem mart Atorvastatin CH MP C4238 C4263 P4263 30 5 30 NP C4263 30 5 30 a Lipitor PF MP C4238 C4263 P4263 30 5 30 NP C4263 30 5 30 a Lorstat 10 AF MP C4238 C4263 P4263 30 5 30 NP C4263 30 5 30 a Terry White Chemists Atorvastatin TW MP C4238 C4263 P4263 30 5 30 NP C4263 30 5 30 a Torvastat 10 RW MP C4238 C4263 P4263 30 5 30 NP C4263 30 5 30 a Trovas RA MP C4238 C4263 P4263 30 5 30 NP C4263 30 5 30 a APO‑Atorvastatin TX MP C4238 C4263 P4238 30 11 30 a Atorvachol ED MP C4238 C4263 P4238 30 11 30 a Atorvastatin Amneal EF MP C4238 C4263 P4238 30 11 30 a Atorvastatin AN EA MP C4238 C4263 P4238 30 11 30 a Atorvastatin GH GQ MP C4238 C4263 P4238 30 11 30 a Atorvastatin Sandoz SZ MP C4238 C4263 P4238 30 11 30 a Atorvastatin SCP 10 RZ MP C4238 C4263 P4238 30 11 30 a Atorvastatin SZ HX MP C4238 C4263 P4238 30 11 30 a Blooms the Chemist Atorvastatin IB MP C4238 C4263 P4238 30 11 30 a Chem mart Atorvastatin CH MP C4238 C4263 P4238 30 11 30 a Lipitor PF MP C4238 C4263 P4238 30 11 30 a Lorstat 10 AF MP C4238 C4263 P4238 30 11 30 a Terry White Chemists Atorvastatin TW MP C4238 C4263 P4238 30 11 30 a Torvastat 10 RW MP C4238 C4263 P4238 30 11 30 a Trovas RA MP C4238 C4263 P4238 30 11 30 Tablet 20 mg (as calcium) Oral a APO‑Atorvastatin TX MP C4238 C4263 P4263 30 5 30 NP C4263 30 5 30 a Atorvachol ED MP C4238 C4263 P4263 30 5 30 NP C4263 30 5 30 a Atorvastatin Amneal EF MP C4238 C4263 P4263 30 5 30 NP C4263 30 5 30 a Atorvastatin AN EA MP C4238 C4263 P4263 30 5 30 NP C4263 30 5 30 a Atorvastatin GH GQ MP C4238 C4263 P4263 30 5 30 NP C4263 30 5 30 a Atorvastatin Sandoz SZ MP C4238 C4263 P4263 30 5 30 NP C4263 30 5 30 a Atorvastatin SCP 20 RZ MP C4238 C4263 P4263 30 5 30 NP C4263 30 5 30 a Atorvastatin SZ HX MP C4238 C4263 P4263 30 5 30 NP C4263 30 5 30 a Blooms the Chemist Atorvastatin IB MP C4238 C4263 P4263 30 5 30 NP C4263 30 5 30 a Chem mart Atorvastatin CH MP C4238 C4263 P4263 30 5 30 NP C4263 30 5 30 a Lipitor PF MP C4238 C4263 P4263 30 5 30 NP C4263 30 5 30 a Lorstat 20 AF MP C4238 C4263 P4263 30 5 30 NP C4263 30 5 30 a Terry White Chemists Atorvastatin TW MP C4238 C4263 P4263 30 5 30 NP C4263 30 5 30 a Torvastat 20 RW MP C4238 C4263 P4263 30 5 30 NP C4263 30 5 30 a Trovas RA MP C4238 C4263 P4263 30 5 30 NP C4263 30 5 30 a APO‑Atorvastatin TX MP C4238 C4263 P4238 30 11 30 a Atorvachol ED MP C4238 C4263 P4238 30 11 30 a Atorvastatin Amneal EF MP C4238 C4263 P4238 30 11 30 a Atorvastatin AN EA MP C4238 C4263 P4238 30 11 30 a Atorvastatin GH GQ MP C4238 C4263 P4238 30 11 30 a Atorvastatin Sandoz SZ MP C4238 C4263 P4238 30 11 30 a Atorvastatin SCP 20 RZ MP C4238 C4263 P4238 30 11 30 a Atorvastatin SZ HX MP C4238 C4263 P4238 30 11 30 a Blooms the Chemist Atorvastatin IB MP C4238 C4263 P4238 30 11 30 a Chem mart Atorvastatin CH MP C4238 C4263 P4238 30 11 30 a Lipitor PF MP C4238 C4263 P4238 30 11 30 a Lorstat 20 AF MP C4238 C4263 P4238 30 11 30 a Terry White Chemists Atorvastatin TW MP C4238 C4263 P4238 30 11 30 a Torvastat 20 RW MP C4238 C4263 P4238 30 11 30 a Trovas RA MP C4238 C4263 P4238 30 11 30 Tablet 40 mg (as calcium) Oral a APO‑Atorvastatin TX MP C4238 C4263 P4263 30 5 30 NP C4263 30 5 30 a Atorvachol ED MP C4238 C4263 P4263 30 5 30 NP C4263 30 5 30 a Atorvastatin Amneal EF MP C4238 C4263 P4263 30 5 30 NP C4263 30 5 30 a Atorvastatin AN EA MP C4238 C4263 P4263 30 5 30 NP C4263 30 5 30 a Atorvastatin GH GQ MP C4238 C4263 P4263 30 5 30 NP C4263 30 5 30 a Atorvastatin Sandoz SZ MP C4238 C4263 P4263 30 5 30 NP C4263 30 5 30 a Atorvastatin SCP 40 RZ MP C4238 C4263 P4263 30 5 30 NP C4263 30 5 30 a Atorvastatin SZ HX MP C4238 C4263 P4263 30 5 30 NP C4263 30 5 30 a Blooms the Chemist Atorvastatin IB MP C4238 C4263 P4263 30 5 30 NP C4263 30 5 30 a Chem mart Atorvastatin CH MP C4238 C4263 P4263 30 5 30 NP C4263 30 5 30 a Lipitor PF MP C4238 C4263 P4263 30 5 30 NP C4263 30 5 30 a Lorstat 40 AF MP C4238 C4263 P4263 30 5 30 NP C4263 30 5 30 a Terry White Chemists Atorvastatin TW MP C4238 C4263 P4263 30 5 30 NP C4263 30 5 30 a Torvastat 40 RW MP C4238 C4263 P4263 30 5 30 NP C4263 30 5 30 a Trovas RA MP C4238 C4263 P4263 30 5 30 NP C4263 30 5 30 a APO‑Atorvastatin TX MP C4238 C4263 P4238 30 11 30 a Atorvachol ED MP C4238 C4263 P4238 30 11 30 a Atorvastatin Amneal EF MP C4238 C4263 P4238 30 11 30 a Atorvastatin AN EA MP C4238 C4263 P4238 30 11 30 a Atorvastatin GH GQ MP C4238 C4263 P4238 30 11 30 a Atorvastatin Sandoz SZ MP C4238 C4263 P4238 30 11 30 a Atorvastatin SCP 40 RZ MP C4238 C4263 P4238 30 11 30 a Atorvastatin SZ HX MP C4238 C4263 P4238 30 11 30 a Blooms the Chemist Atorvastatin IB MP C4238 C4263 P4238 30 11 30 a Chem mart Atorvastatin CH MP C4238 C4263 P4238 30 11 30 a Lipitor PF MP C4238 C4263 P4238 30 11 30 a Lorstat 40 AF MP C4238 C4263 P4238 30 11 30 a Terry White Chemists Atorvastatin TW MP C4238 C4263 P4238 30 11 30 a Torvastat 40 RW MP C4238 C4263 P4238 30 11 30 a Trovas RA MP C4238 C4263 P4238 30 11 30 Tablet 80 mg (as calcium) Oral a APO‑Atorvastatin TX MP C4238 C4263 P4263 30 5 30 NP C4263 30 5 30 a Atorvachol ED MP C4238 C4263 P4263 30 5 30 NP C4263 30 5 30 a Atorvastatin Amneal EF MP C4238 C4263 P4263 30 5 30 NP C4263 30 5 30 a Atorvastatin AN EA MP C4238 C4263 P4263 30 5 30 NP C4263 30 5 30 a Atorvastatin GH GQ MP C4238 C4263 P4263 30 5 30 NP C4263 30 5 30 a Atorvastatin Sandoz SZ MP C4238 C4263 P4263 30 5 30 NP C4263 30 5 30 a Atorvastatin SCP 80 RZ MP C4238 C4263 P4263 30 5 30 NP C4263 30 5 30 a Atorvastatin SZ HX MP C4238 C4263 P4263 30 5 30 NP C4263 30 5 30 a Blooms the Chemist Atorvastatin IB MP C4238 C4263 P4263 30 5 30 NP C4263 30 5 30 a Chem mart Atorvastatin CH MP C4238 C4263 P4263 30 5 30 NP C4263 30 5 30 a Lipitor PF MP C4238 C4263 P4263 30 5 30 NP C4263 30 5 30 a Lorstat 80 AF MP C4238 C4263 P4263 30 5 30 NP C4263 30 5 30 a Terry White Chemists Atorvastatin TW MP C4238 C4263 P4263 30 5 30 NP C4263 30 5 30 a Torvastat 80 RW MP C4238 C4263 P4263 30 5 30 NP C4263 30 5 30 a Trovas RA MP C4238 C4263 P4263 30 5 30 NP C4263 30 5 30 a APO‑Atorvastatin TX MP C4238 C4263 P4238 30 11 30 a Atorvachol ED MP C4238 C4263 P4238 30 11 30 a Atorvastatin Amneal EF MP C4238 C4263 P4238 30 11 30 a Atorvastatin AN EA MP C4238 C4263 P4238 30 11 30 a Atorvastatin GH GQ MP C4238 C4263 P4238 30 11 30 a Atorvastatin Sandoz SZ MP C4238 C4263 P4238 30 11 30 a Atorvastatin SCP 80 RZ MP C4238 C4263 P4238 30 11 30 a Atorvastatin SZ HX MP C4238 C4263 P4238 30 11 30 a Blooms the Chemist Atorvastatin IB MP C4238 C4263 P4238 30 11 30 a Chem mart Atorvastatin CH MP C4238 C4263 P4238 30 11 30 a Lipitor PF MP C4238 C4263 P4238 30 11 30 a Lorstat 80 AF MP C4238 C4263 P4238 30 11 30 a Terry White Chemists Atorvastatin TW MP C4238 C4263 P4238 30 11 30 a Torvastat 80 RW MP C4238 C4263 P4238 30 11 30 a Trovas RA MP C4238 C4263 P4238 30 11 30 Atovaquone Oral suspension 750 mg per 5 mL, 210 mL Oral Wellvone AS MP NP C5609 1 0 1 Atovaquone with proguanil Tablet containing atovaquone 250 mg with proguanil hydrochloride 100 mg Oral Malarone GK MP NP C5981 12 0 12 Atropine Injection containing atropine sulfate 600 micrograms in 1 mL Injection Pfizer Australia Pty Ltd PF PDP 10 0 10 MP NP 10 1 10 Eye drops containing atropine sulfate 10 mg per mL, 15 mL Application to the eye Atropt QA MP NP 1 2 1 Auranofin Tablet 3 mg Oral Ridaura GH MP NP 60 5 60 MP NP 100 3 100 Aurothiomalate Injection containing sodium aurothiomalate 10 mg Injection Myocrisin SW MP NP 10 0 10 Injection containing sodium aurothiomalate 20 mg Injection Myocrisin SW MP NP 10 1 10 Injection containing sodium aurothiomalate 50 mg Injection Myocrisin SW MP NP 10 1 10 Axitinib Tablet 1 mg Oral Inlyta PF MP C5674 C5733 P5733 56 2 28 MP C5674 C5733 P5674 56 5 28 Tablet 5 mg Oral Inlyta PF MP C5674 C5733 P5733 56 2 28 MP C5674 C5733 P5674 56 5 28 Azacitidine Powder for injection 100 mg Injection a Azadine RZ MP See Note 3 See Note 3 See Note 3 See
Note 31 D(100) a Vidaza CJ MP See Note 3 See Note 3 See Note 3 See
Note 31 D(100) Azathioprine Tablet 25 mg Oral APO-Azathioprine TX MP NP 100 5 100 Azathioprine GH GQ MP NP 100 5 100 Azathioprine Sandoz SZ MP NP 100 5 100 Imuran AS MP NP 100 5 100 Tablet 50 mg Oral APO-Azathioprine TX MP NP 100 5 100 Azamun ED MP NP 100 5 100 Azapin RW MP NP 100 5 100 Azathioprine AN EA MP NP 100 5 100 Azathioprine GH GQ MP NP 100 5 100 Azathioprine Sandoz SZ MP NP 100 5 100 Imazan ER MP NP 100 5 100 Imuran AS MP NP 100 5 100 Thioprine 50 AF MP NP 100 5 100 Azithromycin Tablet 500 mg (as dihydrate) Oral APO-Azithromycin TX MP NP C5637 C5718 C5772 P5718 P5772 2 0 2 Azithromycin-GA EA MP NP C5637 C5718 C5772 P5718 P5772 2 0 2 Azithromycin Sandoz SZ MP NP C5637 C5718 C5772 P5718 P5772 2 0 2 Chem mart Azithromycin CH MP NP C5637 C5718 C5772 P5718 P5772 2 0 2 Terry White Chemists Azithromycin TW MP NP C5637 C5718 C5772 P5718 P5772 2 0 2 Zithromax PF MP NP C5637 C5718 C5772 P5718 P5772 2 0 2 APO-Azithromycin TX MP NP C5637 C5718 C5772 P5637 2 2 2 Azithromycin-GA EA MP NP C5637 C5718 C5772 P5637 2 2 2 Azithromycin Sandoz SZ MP NP C5637 C5718 C5772 P5637 2 2 2 Chem mart Azithromycin CH MP NP C5637 C5718 C5772 P5637 2 2 2 Terry White Chemists Azithromycin TW MP NP C5637 C5718 C5772 P5637 2 2 2 Zithromax PF MP NP C5637 C5718 C5772 P5637 2 2 2 Tablet 600 mg (as dihydrate) Oral Zithromax PF MP C1299 C3317 16 5 8 PB(100) Powder for oral suspension 200 mg (as dihydrate) per 5 mL, 15 mL Oral Zithromax PF MP NP C5637 1 0 1 Bacillus Calmette and Guerin, Connaught strain Powder for intravesical administration containing 6.6 to 19.2 x 10 8 CFU Intravesical ImmuCyst SW MP C5578 3 1 1 MP C5598 3 1 1 C(100) Bacillus Calmette and Guerin, Tice strain Vial containing powder for intravesical administration approximately 5 x 10 8 CFU Intravesical OncoTICE MK MP C5540 3 1 3 MP C5597 3 1 3 C(100) Baclofen Tablet 10 mg Oral Chem mart Baclofen CH MP NP 100 5 100 Clofen 10 AF MP NP 100 5 100 GenRx Baclofen GX MP NP 100 5 100 Lioresal 10 NV MP NP 100 5 100 Stelax 10 RW MP NP 100 5 100 Terry White Chemists Baclofen TW MP NP 100 5 100 Tablet 25 mg Oral Chem mart Baclofen CH MP NP 100 5 100 Clofen 25 AF MP NP 100 5 100 GenRx Baclofen GX MP NP 100 5 100 Lioresal 25 NV MP NP 100 5 100 Stelax 25 RW MP NP 100 5 100 Terry White Chemists Baclofen TW MP NP 100 5 100 Intrathecal injection 10 mg in 5 mL Injection a Bacthecal DZ MP C5985 C5990 C6000 C6003 C6025 C6051 C6052 C6054 10 0 1 PB(100) a Lioresal Intrathecal NV MP C5985 C5990 C6000 C6003 C6025 C6051 C6052 C6054 10 0 1 PB(100) Balsalazide Capsule containing balsalazide sodium 750 mg Oral Colazide PK MP NP C4824 180 5 180 Beclomethasone Pressurised inhalation containing beclomethasone dipropionate 50 micrograms per dose, 200 doses (CFC‑free formulation) Inhalation by mouth Qvar 50 IA MP NP 1 5 1 Pressurised inhalation containing beclomethasone dipropionate 100 micrograms per dose, 200 doses (CFC‑free formulation) Inhalation by mouth Qvar 100 IA MP NP 1 5 1 Pressurised inhalation in breath actuated device containing beclomethasone dipropionate 50 micrograms per dose, 200 doses (CFC‑free formulation) Inhalation by mouth Qvar 50 Autohaler IA MP NP C6348 1 5 1 Pressurised inhalation in breath actuated device containing beclomethasone dipropionate 100 micrograms per dose, 200 doses (CFC‑free formulation) Inhalation by mouth Qvar 100 Autohaler IA MP NP C6348 1 5 1 Bendamustine Powder for injection containing bendamustine hydrochloride 25 mg Injection Ribomustin JC MP C6075 C6124 See Note 3 See Note 3 1 D(100) Powder for injection containing bendamustine hydrochloride 100 mg Injection Ribomustin JC MP C6075 C6124 See Note 3 See Note 3 1 D(100) Benzathine benzylpenicillin Injection 900 mg in 2.3 mL single use pre‑filled syringe Injection Bicillin L‑A PF MP NP PDP 10 0 10 Benzhexol Tablet containing benzhexol hydrochloride 2 mg Oral Artane RW MP NP 200 2 200 Tablet containing benzhexol hydrochloride 5 mg Oral Artane RW MP NP 200 1 200 Benztropine Tablet containing benztropine mesylate 2 mg Oral Benztrop PL MP NP 60 2 60 Injection containing benztropine mesylate 2 mg in 2 mL Injection Cogentin FK MP NP PDP 5 0 5 Injection containing benztropine mesylate 2 mg in 2 mL vial Injection Benztropine Omega FK MP NP PDP 10 0 10 Benzydamine Mouth and throat rinse containing benzydamine hydrochloride 22.5 mg per 15 mL, 500 mL Oral application Difflam IA PDP C5732 1 0 1 MP NP C5672 C6197 P5672 1 1 1 MP NP C5672 C6197 P6197 1 3 1 Benzylpenicillin Powder for injection 600 mg (as sodium) Injection BenPen CS PDP 10 0 1 MP NP MW 10 1 1 Powder for injection 3 g (as sodium) Injection BenPen CS MP NP PDP 10 0 1 Betaine Oral powder 180 g Oral Cystadane EU MP C4599 1 5 1 Betamethasone Injection containing betamethasone acetate 3 mg with betamethasone sodium phosphate 3.9 mg in 1 mL Injection Celestone Chronodose MK MP NP C6210 C6211 C6212 C6253 C6254 C6255 C6268 C6269 C6281 5 0 5 PDP C6209 C6237 C6291 5 0 5 Cream 500 micrograms (as dipropionate) per g, 15 g Application a Diprosone MK MP NP C4957 C6218 C6231 C6232 C6246 C6263 P4957 1 1 1 a Eleuphrat FR MP NP C4957 C6218 C6231 C6232 C6246 C6263 P4957 1 1 1 a Diprosone MK MP NP C4957 C6218 C6231 C6232 C6246 C6263 P6232 2 5 1 a Eleuphrat FR MP NP C4957 C6218 C6231 C6232 C6246 C6263 P6232 2 5 1 a Diprosone MK MP NP C4957 C6218 C6231 C6232 C6246 C6263 P6246 4 5 1 a Eleuphrat FR MP NP C4957 C6218 C6231 C6232 C6246 C6263 P6246 4 5 1 a Diprosone MK MP NP C4957 C6218 C6231 C6232 C6246 C6263 P6218 6 5 1 a Eleuphrat FR MP NP C4957 C6218 C6231 C6232 C6246 C6263 P6218 6 5 1 a Diprosone MK MP NP C4957 C6218 C6231 C6232 C6246 C6263 P6263 8 5 1 a Eleuphrat FR MP NP C4957 C6218 C6231 C6232 C6246 C6263 P6263 8 5 1 a Diprosone MK MP NP C4957 C6218 C6231 C6232 C6246 C6263 P6231 10 5 1 a Eleuphrat FR MP NP C4957 C6218 C6231 C6232 C6246 C6263 P6231 10 5 1 Ointment 500 micrograms (as dipropionate) per g, 15 g Application a Diprosone MK MP NP C4957 C6218 C6231 C6232 C6246 C6263 P4957 1 1 1 a Eleuphrat FR MP NP C4957 C6218 C6231 C6232 C6246 C6263 P4957 1 1 1 a Diprosone MK MP NP C4957 C6218 C6231 C6232 C6246 C6263 P6232 2 5 1 a Eleuphrat FR MP NP C4957 C6218 C6231 C6232 C6246 C6263 P6232 2 5 1 a Diprosone MK MP NP C4957 C6218 C6231 C6232 C6246 C6263 P6246 4 5 1 a Eleuphrat FR MP NP C4957 C6218 C6231 C6232 C6246 C6263 P6246 4 5 1 a Diprosone MK MP NP C4957 C6218 C6231 C6232 C6246 C6263 P6218 6 5 1 a Eleuphrat FR MP NP C4957 C6218 C6231 C6232 C6246 C6263 P6218 6 5 1 a Diprosone MK MP NP C4957 C6218 C6231 C6232 C6246 C6263 P6263 8 5 1 a Eleuphrat FR MP NP C4957 C6218 C6231 C6232 C6246 C6263 P6263 8 5 1 a Diprosone MK MP NP C4957 C6218 C6231 C6232 C6246 C6263 P6231 10 5 1 a Eleuphrat FR MP NP C4957 C6218 C6231 C6232 C6246 C6263 P6231 10 5 1 Cream 200 micrograms (as valerate) per g, 100 g Application a Antroquoril FR MP NP C4924 2 0 1 b Betnovate 1/5 QA MP NP C4924 2 0 1 a Celestone-M MK MP NP C4924 2 0 1 b Cortival 1/5 FM MP NP C4924 2 0 1 Cream 500 micrograms (as valerate) per g, 15 g Application a Betnovate 1/2 QA MP NP C4957 C6218 C6231 C6232 C6246 C6263 P4957 1 1 1 a Cortival 1/2 FM MP NP C4957 C6218 C6231 C6232 C6246 C6263 P4957 1 1 1 a Betnovate 1/2 QA MP NP C4957 C6218 C6231 C6232 C6246 C6263 P6232 2 5 1 a Cortival 1/2 FM MP NP C4957 C6218 C6231 C6232 C6246 C6263 P6232 2 5 1 a Betnovate 1/2 QA MP NP C4957 C6218 C6231 C6232 C6246 C6263 P6246 4 5 1 a Cortival 1/2 FM MP NP C4957 C6218 C6231 C6232 C6246 C6263 P6246 4 5 1 a Betnovate 1/2 QA MP NP C4957 C6218 C6231 C6232 C6246 C6263 P6218 6 5 1 a Cortival 1/2 FM MP NP C4957 C6218 C6231 C6232 C6246 C6263 P6218 6 5 1 a Betnovate 1/2 QA MP NP C4957 C6218 C6231 C6232 C6246 C6263 P6263 8 5 1 a Cortival 1/2 FM MP NP C4957 C6218 C6231 C6232 C6246 C6263 P6263 8 5 1 a Betnovate 1/2 QA MP NP C4957 C6218 C6231 C6232 C6246 C6263 P6231 10 5 1 a Cortival 1/2 FM MP NP C4957 C6218 C6231 C6232 C6246 C6263 P6231 10 5 1 Betaxolol Eye drops, suspension, 2.5 mg (as hydrochloride) per mL, 5 mL Application to the eye Betoptic S AQ MP AO 1 5 1 Eye drops, solution, 5 mg (as hydrochloride) per mL, 5 mL Application to the eye Betoptic AQ MP AO 1 5 1 BetoQuin IQ MP AO 1 5 1 Bethanechol Tablet containing bethanechol hydrochloride 10 mg Oral Uro‑Carb YN MP NP 100 2 100 Bevacizumab Solution for I.V. infusion 100 mg in 4 mL Injection Avastin RO MP C4584 C4587 C4594 C4814 C4939 C4968 C6337 C6338 C6353 See Note 3 See
Note 31 D(100) Solution for I.V. infusion 400 mg in 16 mL Injection Avastin RO MP C4584 C4587 C4594 C4814 C4939 C4968 C6337 C6338 C6353 See Note 3 See
Note 31 D(100) Bicalutamide Tablet 50 mg Oral a APO‑
BicalutamideTX MP NP C5729 28 5 28 a Bicalox ER MP NP C5729 28 5 28 a Bicalutamide AN EA MP NP C5729 28 5 28 a Calutex QA MP NP C5729 28 5 28 a Cosamide 50 AF MP NP C5729 28 5 28 a Cosudex AP MP NP C5729 28 5 28 Bimatoprost Eye drops 300 micrograms per mL, 3 mL Application to the eye Lumigan AG MP AO 1 5 1 Eye drops 300 micrograms per mL, single dose units 0.4 mL, 30 Application to the eye Lumigan PF AG MP AO 1 5 1 Bimatoprost with timolol Eye drops 300 micrograms bimatoprost with timolol 5 mg (as maleate) per mL, 3 mL Application to the eye Ganfort 0.3/5 AG MP C4343 1 5 1 AO C5038 1 5 1 Eye drops 300 micrograms bimatoprost with timolol 5 mg (as maleate) per mL, single dose units 0.4 mL, 30 Application to the eye GANfort PF 0.3/5 AG MP C4572 1 5 1 AO C5038 1 5 1 Biperiden Tablet containing biperiden hydrochloride 2 mg Oral Akineton ZC MP NP 200 2 100 Bisacodyl Suppositories 10 mg, 10 Rectal a Dulcolax BY MP NP C5640 C5775 C5819 C5823 C5851 C5866 C5879 C6139 P6139 3 3 1 a Petrus Bisacodyl Suppositories PP MP NP C5640 C5775 C5819 C5823 C5851 C5866 C5879 C6139 P6139 3 3 1 a Dulcolax BY MP NP C5640 C5775 C5819 C5823 C5851 C5866 C5879 C6139 P5640 P5775 P5819 P5823 P5851 P5866 P5879 3 5 1 a Petrus Bisacodyl Suppositories PP MP NP C5640 C5775 C5819 C5823 C5851 C5866 C5879 C6139 P5640 P5775 P5819 P5823 P5851 P5866 P5879 3 5 1 a Dulcolax BY MP See Note 2 See Note 2 See Note 2 See Note 2 1 C(100) a Petrus Bisacodyl Suppositories PP MP See Note 2 See Note 2 See Note 2 See Note 2 1 C(100) Suppositories 10 mg, 12 Rectal Petrus Bisacodyl Suppositories PP MP NP C5640 C5775 C5819 C5823 C5851 C5866 C5879 C6139 P6139 3 3 1 MP NP C5640 C5775 C5819 C5823 C5851 C5866 C5879 C6139 P5640 P5775 P5819 P5823 P5851 P5866 P5879 3 4 1 MP See Note 2 See Note 2 See Note 2 See Note 2 1 C(100) Enemas 10 mg in 5 mL, 25 Rectal Bisalax AS MP NP C5613 C5640 C5685 C5720 C5775 C5776 C5804 C6139 P5613 P5640 P5685 P5720 P5775 P5776 P5804 1 2 1 MP NP C5613 C5640 C5685 C5720 C5775 C5776 C5804 C6139 P6139 1 3 1 MP See Note 2 See Note 2 See Note 2 See Note 2 1 C(100) Tablet 5 mg Oral Lax-Tab AE MP NP C5613 C5640 C5685 C5720 C5775 C5776 C5804 C6139 P5613 P5640 P5685 P5720 P5775 P5776 P5804 200 2 200 MP NP C5613 C5640 C5685 C5720 C5775 C5776 C5804 C6139 P6139 200 3 200 MP See Note 2 See Note 2 See Note 2 See Note 2 200 C(100) Bisoprolol Tablet containing bisoprolol fumarate 2.5 mg Oral APO‑Bisoprolol TX MP NP C5324 28 5 28 Beprol 2.5 DO MP NP C5324 28 5 28 Bicard 2.5 RW MP NP C5324 28 5 28 Bicor AL MP NP C5324 28 5 28 Biso 2.5 ED MP NP C5324 28 5 28 Bisoprolol AN EA MP NP C5324 28 5 28 Bisoprolol generichealth GQ MP NP C5324 28 5 28 Bisoprolol Sandoz SZ MP NP C5324 28 5 28 Bispro 2.5 AF MP NP C5324 28 5 28 Chem mart Bisoprolol CH MP NP C5324 28 5 28 Terry White Chemists Bisoprolol TW MP NP C5324 28 5 28 Tablet containing bisoprolol fumarate 5 mg Oral APO‑Bisoprolol TX MP NP C5324 28 5 28 Beprol 5 DO MP NP C5324 28 5 28 Bicard 5 RW MP NP C5324 28 5 28 Bicor AL MP NP C5324 28 5 28 Biso 5 ED MP NP C5324 28 5 28 Bisoprolol AN EA MP NP C5324 28 5 28 Bisoprolol generichealth GQ MP NP C5324 28 5 28 Bisoprolol Sandoz SZ MP NP C5324 28 5 28 Bispro 5 AF MP NP C5324 28 5 28 Chem mart Bisoprolol CH MP NP C5324 28 5 28 Terry White Chemists Bisoprolol TW MP NP C5324 28 5 28 Tablet containing bisoprolol fumarate 10 mg Oral APO‑Bisoprolol TX MP NP C5324 28 5 28 Beprol 10 DO MP NP C5324 28 5 28 Bicard 10 RW MP NP C5324 28 5 28 Bicor AL MP NP C5324 28 5 28 Biso 10 ED MP NP C5324 28 5 28 Bisoprolol AN EA MP NP C5324 28 5 28 Bisoprolol generichealth GQ MP NP C5324 28 5 28 Bisoprolol Sandoz SZ MP NP C5324 28 5 28 Bispro 10 AF MP NP C5324 28 5 28 Chem mart Bisoprolol CH MP NP C5324 28 5 28 Terry White Chemists Bisoprolol TW MP NP C5324 28 5 28 Bivalirudin Powder for I.V. injection 250 mg (as trifluoroacetate) Injection a Angiomax XM MP C4919 1 0 1 a Bivalirudin APOTEX TX MP C4919 1 0 1 Bleomycin Powder for injection containing bleomycin sulfate 15,000 I.U. Injection Bleo 15K EA MP C6224 C6275 See Note 3 See
Note 31 D(100) CIPLA BLEOMYCIN LR MP C6224 C6275 See Note 3 See
Note 31 D(100) Hospira Pty Limited HH MP C6224 C6275 See Note 3 See
Note 31 D(100) Boceprevir Capsule 200 mg Oral Victrelis MK MP C4182 C4196 C4202 C4205 336 10 336 D(100) Bortezomib Powder for injection 1 mg Injection Velcade JC MP C6372 C6384 C6466 C6472 C6478 See Note 3 See
Note 31 D(100) Powder for injection 3 mg Injection Velcade JC MP C4080 C4081 C4161 C4162 C6372 C6373 C6384 C6452 C6466 C6472 C6478 See Note 3 See
Note 31 D(100) Powder for injection 3.5 mg Injection Velcade JC MP C4080 C4081 C4161 C4162 C6373 C6452 See Note 3 See
Note 31 D(100) Bosentan Tablet 62.5 mg (as monohydrate) Oral Tracleer AT MP See Note 3 See Note 3 See Note 3 See
Note 360 D(100) Tablet 125 mg (as monohydrate) Oral Tracleer AT MP See Note 3 See Note 3 See Note 3 See
Note 360 D(100) Botulinum toxin type A purified neurotoxin complex Lyophilised powder for injection 100 units Injection Botox AG MP C5178 C5220 C5221 C5261 C5262 C5333 C5359 C5406 C5407 C5408 C5409 4 0 1 D(100) Brentuximab vedotin Powder for I.V. infusion 50 mg Injection Adcetris TK MP C4675 C4719 See Note 3 See
Note 31 D(100) Brimonidine Eye drops containing brimonidine tartrate 1.5 mg per mL, 5 mL Application to the eye Alphagan P 1.5 AG MP AO 1 5 1 Eye drops containing brimonidine tartrate 2 mg per mL, 5 mL Application to the eye Alphagan AG MP AO 1 5 1 Enidin PE MP AO 1 5 1 Brimonidine with timolol Eye drops containing brimonidine tartrate 2 mg with timolol 5 mg (as maleate) per mL, 5 mL Application to the eye Combigan AG MP C4343 1 5 1 AO C5038 1 5 1 Brinzolamide Eye drops 10 mg per mL, 5 mL Application to the eye Azopt AQ MP AO 1 5 1 BrinzoQuin IQ MP AO 1 5 1 Brinzolamide with brimonidine Eye drops 10 mg brinzolamide with 2 mg brimonidine tartrate per mL, 5 mL Application to the eye Simbrinza 1%/0.2% AQ MP C5630 1 5 1 AO C5038 1 5 1 Brinzolamide with timolol Eye drops 10 mg brinzolamide with timolol 5 mg (as maleate) per mL, 5 mL Application to the eye Azarga AQ MP C4343 1 5 1 AO C5038 1 5 1 Bromocriptine Tablet 2.5 mg (as mesylate) Oral Kripton 2.5 AF MP C5134 C5170 C5171 C5172 C5213 C5356 C5397 P5172 30 0 30 NP C5172 30 0 30 Parlodel SZ MP C5134 C5170 C5171 C5172 C5213 C5356 C5397 P5172 30 0 30 NP C5172 30 0 30 Kripton 2.5 AF MP C5134 C5170 C5171 C5172 C5213 C5356 C5397 P5134 P5170 P5171 P5213 P5356 P5397 60 5 60 Parlodel SZ MP C5134 C5170 C5171 C5172 C5213 C5356 C5397 P5134 P5170 P5171 P5213 P5356 P5397 60 5 30 Budesonide Nebuliser suspension 500 micrograms in 2 mL single dose units, 30 Inhalation Pulmicort Respules AP MP NP C6340 1 5 1 Nebuliser suspension 1 mg in 2 mL single dose units, 30 Inhalation Pulmicort Respules AP MP NP C6340 1 5 1 Powder for oral inhalation in breath actuated device 100 micrograms per dose, 200 doses Inhalation by mouth Pulmicort Turbuhaler AP MP NP 1 5 1 Powder for oral inhalation in breath actuated device 200 micrograms per dose, 200 doses Inhalation by mouth Pulmicort Turbuhaler AP MP NP 1 5 1 Powder for oral inhalation in breath actuated device 400 micrograms per dose, 200 doses Inhalation by mouth Pulmicort Turbuhaler AP MP NP 1 5 1 Rectal foam 2 mg per application, 14 applications, aerosol 16.8 g, 2 Rectal Budenofalk OA MP NP 1 3 1 Budesonide with eformoterol Powder for oral inhalation in breath actuated device containing budesonide 100 micrograms with eformoterol fumarate dihydrate 6 micrograms per dose, 120 doses Inhalation by mouth Symbicort Turbuhaler 100/6 AP MP NP C4380 1 5 1 Powder for oral inhalation in breath actuated device containing budesonide 200 micrograms with eformoterol fumarate dihydrate 6 micrograms per dose, 120 doses Inhalation by mouth Symbicort Turbuhaler 200/6 AP MP NP C4380 1 5 1 Powder for oral inhalation in breath actuated device containing budesonide 400 micrograms with eformoterol fumarate dihydrate 12 micrograms per dose,
60 doses, 2Inhalation by mouth Symbicort Turbuhaler 400/12 AP MP NP C4394 C4689 1 5 1 Pressurised inhalation containing budesonide 50 micrograms with eformoterol fumarate dihydrate 3 micrograms per dose, 120 doses Inhalation by mouth Symbicort Rapihaler 50/3 AP MP NP C4397 2 5 1 Pressurised inhalation containing budesonide 100 micrograms with eformoterol fumarate dihydrate 3 micrograms per dose, 120 doses Inhalation by mouth Symbicort Rapihaler 100/3 AP MP NP C4397 2 5 1 Pressurised inhalation containing budesonide 200 micrograms with eformoterol fumarate dihydrate 6 micrograms per dose, 120 doses Inhalation by mouth Symbicort Rapihaler 200/6 AP MP NP C4404 C4689 2 5 1 Buprenorphine Tablet (sublingual) 400 micrograms (as hydrochloride) Sublingual Subutex IR MP NP C6451 See Note 3 See
Note 37 PB(100) Tablet (sublingual) 2 mg (as hydrochloride) Sublingual Subutex IR MP NP C6451 See Note 3 See
Note 37 PB(100) Tablet (sublingual) 8 mg (as hydrochloride) Sublingual Subutex IR MP NP C6451 See Note 3 See
Note 37 PB(100) Transdermal patch 5 mg Transdermal Norspan MF MP NP C4951 C6151 P4951 2 0 2 MP NP C4951 C6151 P6151 4 2 2 Transdermal patch 10 mg Transdermal Norspan MF MP NP C4951 C6151 P4951 2 0 2 MP NP C4951 C6151 P6151 4 2 2 Transdermal patch 15 mg Transdermal Norspan MF MP NP C4951 C6151 P4951 2 0 2 MP NP C4951 C6151 P6151 4 2 2 Transdermal patch 20 mg Transdermal Norspan MF MP NP C4951 C6151 P4951 2 0 2 MP NP C4951 C6151 P6151 4 2 2 Transdermal patch 25 mg Transdermal Norspan MF MP NP C4951 C6151 P4951 2 0 2
Note: The name of the listed drug is included in this table to assist in identifying the circumstances applying to the pharmaceutical benefits that have a particular drug.
Part 2—General statement for lipid‑lowering drugs
1 Criteria for eligibility for lipid‑lowering drugs
(1) The criteria for patient eligibility for lipid‑lowering drugs are that:
(a) the patient:
(i) is in a very high risk category; and
(ii) dietary therapy will commence simultaneously with the drug therapy; and
(iii) dietary therapy will continue concurrently with the drug therapy and will be reviewed at least annually; or
(b) the patient:
(i) has been assessed in accordance with clause 2 and meets the lipid levels for PBS subsidy set out in clause 3; and
(ii) dietary therapy will continue concurrently with the drug therapy and will be reviewed at least annually.
Note: Patients mentioned in paragraph (b)(i) must be trialled on dietary therapy prior to commencing the drug therapy—see the flowchart in clause 2.
(2) In this clause, a patient is in a very high risk category if the patient has:
(a) coronary heart disease that has become symptomatic; or
(b) cerebrovascular disease that has become symptomatic; or
(c) peripheral vascular disease that has become symptomatic; or
(d) diabetes mellitus with microalbuminuria where the patient has:
(i) a urinary albumin excretion rate of >20 mcg/min; or
(ii) a urinary albumin to creatinine ratio of:
(A) > 2.5 for a male patient; or
(B) > 3.5 for a female patient; or
(e) diabetes mellitus and the patient is:
(i) an Aboriginal or Torres Strait Islander; or
(ii) aged 60 years or over; or
(f) a family history of coronary heart disease that has become symptomatic before the age of 55 years in 2 or more first degree relatives; or
(g) a family history of coronary heart disease that has become symptomatic before the age of 45 years in 1 or more first degree relatives.
2 Assessment of patient
For subparagraph 1(1)(b)(i), the patient has been assessed as set out in the following flowchart:
3 Lipid levels
(1) For subparagraph 1(1)(b)(i), a patient meets the lipid levels for PBS subsidy if the patient:
(a) is a kind of patient mentioned for an item in column 2 of the following table; and
(b) has a lipid level, measured by an accredited laboratory, mentioned in column 3 of the table for that item.
Item Kind of patient Lipid levels 1 Patient with diabetes mellitus Total cholesterol > 5.5 mmol/L 2 Aboriginal or Torres Strait Islander patient with hypertension Either:
(a) total cholesterol > 6.5 mmol/L; or
(b) total cholesterol > 5.5 mmol/L and HDL cholesterol < 1 mmol/L
3 Patient with HDL cholesterol <1 mmol/L Total cholesterol > 6.5 mmol/L 4 Patient with:
(a) familial hypercholesterolaemia identified by:
(i) tendon xanthomas in the patient or a first or second degree relative of the patient; or
(i) DNA mutation; or
(b) a family history of coronary heart disease which has become symptomatic:
(i) before the age of 60 years in 1 or more first degree relatives; or
(ii) before the age of 50 years in 1 or more second degree relatives
Either:
(a) if the patient is aged 18 years or less at time of treatment initiation—LDL cholesterol > 4 mmol/L; or
(b) if patient is aged more than 18 years at time of treatment initiation:
(i) LDL cholesterol > 5 mmol/L; or
(ii) total cholesterol > 6.5 mmol/L; or
(iii) total cholesterol > 5.5 mmol/L and HDL cholesterol < 1 mmol/L
5 Either:
(a) male patient aged between 35 and 75 years (inclusive); or
(b) female patient, post‑menopausal and aged 75 years or less
Either:
(a) total cholesterol > 7.5 mmol/L; or
(b) triglyceride > 4 mmol/L
6 Any other patient Either:
(a) total cholesterol > 9 mmol/L; or
(b) triglyceride > 8 mmol/L
(2) In this clause:
accredited laboratory means:
(a) premises approved under section 23DN of the Health Insurance Act 1973; or
(b) a laboratory accredited in accordance with standards set by the National Pathology Accreditation Advisory Council established under subsection 9(1) of the National Health Act 1953.
Part 3—General statement for drugs for the treatment of hepatitis C
1 Criteria for eligibility for drugs for the treatment of chronic hepatitis C
The criteria for patient eligibility for drugs for the treatment of chronic hepatitis C are that:
(1) the patient is 18 years or older; and
(2) the patient has been assessed in accordance with paragraph 2 of this Part; and
(3) the patient is:
a. treated by a medical practitioner who is experienced in the treatment of patients with chronic hepatitis C infection; or
b. treated in consultation with a medical practitioner who is experienced in the treatment of patients with chronic hepatitis C infection and who is:
i. a gastroenterologist; or
ii. a hepatologist; or
iii. an infectious diseases physician
2 Assessment of patient
For the purpose of subparagraph 1(2) of this Part, the patient has been assessed if the treating medical practitioner has:
(1) documented the following information in the patient’s medical records:
a. evidence of chronic hepatitis C infection; and
b. evidence of the patient’s hepatitis C virus genotype; and
(2) chosen a regimen in accordance with paragraph 3 of this Part; and
(3) collected the following information for the purposes of the authority application:
a. the patient’s hepatitis C virus genotype; and
b. whether the patient is:
i. cirrhotic; or
ii. Non-cirrhotic
(4) In this paragraph, evidence of chronic hepatitis C infection is documentation of:
a. repeat test results showing antibody to hepatitis C virus (anti-HCV) positive; and
b. test result showing hepatitis C virus ribonucleic acid (RNA) positive
3 Treatment regimen
For the purpose of subparagraph 2(2) of this Part, the treating medical practitioner has chosen a regimen in accordance with this paragraph if the patient:
(1) is a kind of patient mentioned for an Item in column 2 of the following table; and
(2) is to receive one of the regimens mentioned in column 3 of the same Item of the following table
Item Kind of patient Regimen 1 Patient:
(a) with Genotype 1; and
(b) who is treatment naïve; and
(c) who is non-cirrhotic
Either:
(a) LEDIPASVIR with SOFOSBUVIR for 8 weeks; or
(b) LEDIPASVIR with SOFOSBUVIR for 12 weeks; or
(c) DACLATASVIR and SOFOSBUVIR for 12 weeks; or
(d) SOFOSBUVIR and PEGINTERFERON ALFA-2A with RIBAVIRIN for 12 weeks; or
(e) PARITAPREVIR with RITONAVIR with OMBITASVIR and DASABUVIR for 12 weeks; or
(f) PARITAPREVIR with RITONAVIR with OMBITASVIR and DASABUVIR and RIBAVIRIN for 12 weeks.
2 Patient:
(a) with Genotype 1; and
(b) who is treatment experienced; and
(c) who is non-cirrhotic
Either:
(a) LEDIPASVIR with SOFOSBUVIR for 12 weeks; or
(b) DACLATASVIR and SOFOSBUVIR for 12 weeks; or
(c) DACLATASVIR and SOFOSBUVIR for 24 weeks; or
(d) SOFOSBUVIR and PEGINTERFERON ALFA-2A with RIBAVIRIN for 12 weeks; or
(e) PARITAPREVIR with RITONAVIR with OMBITASVIR and DASABUVIR for 12 weeks; or
(f) PARITAPREVIR with RITONAVIR with OMBITASVIR and DASABUVIR and RIBAVIRIN for 12 weeks.
3 Patient:
(a) with Genotype 2; and
(b) who is treatment naïve; and
(c) who is non-cirrhotic
SOFOSBUVIR and RIBAVIRIN for 12 weeks.
4 Patient:
(a) with Genotype 2; and
(b) who is treatment experienced; and
(c) who is non-cirrhotic
SOFOSBUVIR and RIBAVIRIN for 12 weeks.
5 Patient:
(a) with Genotype 3; and
(b) who is treatment naïve; and
(c) who is non-cirrhotic
Either:
(a) DACLATASVIR and SOFOSBUVIR for 12 weeks; or
(b) SOFOSBUVIR and RIBAVIRIN for 24 weeks; or
(c) SOFOSBUVIR and PEGINTERFERON ALFA-2A with RIBAVIRIN for 12 weeks.
6 Patient:
(a) with Genotype 3; and
(b) who is treatment experienced; and
(c) who is non-cirrhotic
Either:
(a) DACLATASVIR and SOFOSBUVIR for 12 weeks; or
(b) SOFOSBUVIR and RIBAVIRIN for 24 weeks; or
(c) SOFOSBUVIR and PEGINTERFERON ALFA-2A with RIBAVIRIN for 12 weeks.
7 Patient:
(a) with:
(i) Genotype 4; or
(ii) Genotype 5; or
(iii) Genotype 6; and
(b) who is treatment naïve; and
(c) who is non-cirrhotic
SOFOSBUVIR and PEGINTERFERON ALFA-2A with RIBAVIRIN for 12 weeks.
8 Patient:
(a) with:
(i) Genotype 4; or
(ii) Genotype 5; or
(iii) Genotype 6; and
(b) who is treatment experienced; and
(c) who is non-cirrhotic
SOFOSBUVIR and PEGINTERFERON ALFA-2A with RIBAVIRIN for 12 weeks.
9 Patient:
(a) with Genotype 1; and
(b) who is treatment naïve; and
(c) who is cirrhotic
Either:
(a) LEDIPASVIR with SOFOSBUVIR for 12 weeks; or
(b) DACLATASVIR and SOFOSBUVIR and RIBAVIRIN for 12 weeks; or
(c) DACLATASVIR and SOFOSBUVIR for 24 weeks; or
(d) SOFOSBUVIR and PEGINTERFERON ALFA-2A with RIBAVIRIN for 12 weeks; or
(e) PARITAPREVIR with RITONAVIR with OMBITASVIR and DASABUVIR and RIBAVIRIN for 12 weeks.
10 Patient:
(a) with Genotype 1; and
(b) who is treatment experienced; and
(c) who is cirrhotic
Either:
(a) LEDIPASVIR with SOFOSBUVIR for 24 weeks; or
(b) DACLATASVIR and SOFOSBUVIR for 24 weeks; or
(c) DACLATASVIR and SOFOSBUVIR and RIBAVIRIN for 12 weeks; or
(d) SOFOSBUVIR and PEGINTERFERON ALFA-2A with RIBAVIRIN for 12 weeks; or
(e) PARITAPREVIR with RITONAVIR with OMBITASVIR and DASABUVIR and RIBAVIRIN for 12 weeks; or
(f) PARITAPREVIR with RITONAVIR with OMBITASVIR and DASABUVIR and RIBAVIRIN for 24 weeks.
11 Patient:
(a) with Genotype 2; and
(b) who is treatment naïve; and
(c) who is cirrhotic
SOFOSBUVIR and RIBAVIRIN for 12 weeks.
12 Patient:
(a) with Genotype 2; and
(b) who is treatment experienced; and
(c) who is cirrhotic
SOFOSBUVIR and RIBAVIRIN for 12 weeks.
13 Patient:
(a) with Genotype 3; and
(b) who is treatment naïve; and
(c) who is cirrhotic
Either:
(a) SOFOSBUVIR and RIBAVIRIN for 24 weeks; or
(b) DACLATASVIR and SOFOSBUVIR for 24 weeks; or
(c) SOFOSBUVIR and PEGINTERFERON ALFA-2A with RIBAVIRIN for 12 weeks; or
(d) DACLATASVIR and SOFOSBUVIR and RBV for 12 weeks; or
(e) DACLATASVIR and SOFOSBUVIR and RBV for 24 weeks.
14 Patient:
(a) with Genotype 3; and
(b) who is treatment experienced; and
(c) who is cirrhotic
Either:
(a) DACLATASVIR and SOFOSBUVIR for 24 weeks; or
(b) SOFOSBUVIR and RIBAVIRIN for 24 weeks; or
(c) SOFOSBUVIR and PEGINTERFERON ALFA-2A with RIBAVIRIN for 12 weeks; or
(d) DACLATASVIR and SOFOSBUVIR and RBV for 12 weeks; or
(e) DACLATASVIR and SOFOSBUVIR and RBV for 24 weeks.
15 Patient:
(a) with:
(i) Genotype 4; or
(ii) Genotype 5; or
(iii) Genotype 6; and
(b) who is treatment naïve; and
(c) who is cirrhotic
SOFOSBUVIR and PEGINTERFERON ALFA-2A with RIBAVIRIN for 12 weeks.
16 Patient:
(a) with:
(i) Genotype 4; or
(ii) Genotype 5; or
(iii) Genotype 6; and
(b) who is treatment experienced; and
(c) who is cirrhotic
SOFOSBUVIR and PEGINTERFERON ALFA-2A with RIBAVIRIN for 12 weeks.
Schedule 5—Schedule equivalent
(section 8A)
Listed Drug Schedule Equivalent Group Form Manner of Administration Brand Clopidogrel
GRP-15475 Tablet 75 mg (as besilate) Oral Clopidogrel-GA
Clovix 75
Plidogrel
Tablet 75 mg (as hydrogen sulfate) Oral APO-Clopidogrel
Blooms the Chemist Clopidogrel
Chem mart Clopidogrel
Clopidogrel AN
Clopidogrel Winthrop
Iscover
Piax
Plavix
Terry White Chemists Clopidogrel
GRP-17110 Tablet 75 mg Oral Clopidogrel-DRLA Tablet 75 mg (as besilate) Oral Clopidogrel GH
Clopidogrel-GA
Clovix 75
Plidogrel
Tablet 75 mg (as hydrogen sulfate) Oral APO-Clopidogrel
Blooms the Chemist Clopidogrel
Chem mart Clopidogrel
Clopidogrel AN
Clopidogrel RBX
Clopidogrel Sandoz
Clopidogrel Winthrop
Iscover
Piax
Plavicor 75
Plavix
Terry White Chemists Clopidogrel
Desvenlafaxine GRP-16219 Tablet (extended release) 100 mg (as succinate) Oral Pristiq Tablet (modified release) 100 mg Oral Desvenlafaxine Sandoz
Desvenlafaxine Actavis
DesfaxTablet (modified release) 100 mg (as benzoate) Oral Desvenlafaxine GH XR
APO-Desvenlafaxine MRGRP-16220 Tablet (extended release) 50 mg (as succinate) Oral Pristiq Tablet (modified release) 50 mg Oral Desvenlafaxine Sandoz
Desvenlafaxine Actavis
DesfaxTablet (modified release) 50 mg (as benzoate) Oral Desvenlafaxine GH XR
APO-Desvenlafaxine MREsomeprazole GRP-17188 Capsule (enteric) 20 mg (as magnesium) Oral Esomeprazole ACTAVIS
Noxicid Caps
Tablet (enteric coated) 20 mg (as magnesium trihydrate) Oral Esomeprazole AN
Esomeprazole Apotex
Esomeprazole GH
Esomeprazole GxP
Esomeprazole RBX
Esomeprazole Sandoz
Nexazole
Nexium
Nexole
GRP-17061 Capsule (enteric) 40 mg (as magnesium) Oral Esomeprazole ACTAVIS
Noxicid Caps
Tablet (enteric coated) 40 mg (as magnesium trihydrate) Oral Esomeprazole AN
Esomeprazole Apotex
Esomeprazole GH
Esomeprazole GxP
Esomeprazole RBX
Esomeprazole Sandoz
Nexazole
Nexium
Nexole
Esomeprazole and Clarithromycin and Amoxycillin GRP-20639 Pack containing 14 tablets (enteric coated) containing esomeprazole 20 mg (as magnesium), 14 tablets clarithromycin 500 mg and 28 capsules amoxycillin 500 mg (as trihydrate) Oral ESOMEPRAZOLE SANDOZ Hp7 Pack containing 14 tablets (enteric coated) containing esomeprazole 20 mg (as magnesium trihydrate), 14 tablets clarithromycin 500 mg and 28 capsules amoxycillin 500 mg (as trihydrate) Oral Nexium Hp7 Hydroxocobalamin GRP-17689 Injection 1 mg (as acetate) in 1 mL Injection Vita-B12 Injection 1 mg (as chloride) in 1 mL Injection Hydroxo-B12
Neo-B12Imatinib GRP-21074 Capsule 100 mg (as mesilate) Oral Imatinib-APOTEX Capsule 100 mg (as mesilate) Oral IMATINIB-DRLA Tablet 100 mg (as mesilate) Oral Glivec
IMATINIB RBX
Imatinib-Teva
GRP-21076 Capsule 100 mg (as mesilate) Oral Imatinib-APOTEX Capsule 100 mg (as mesilate) Oral IMATINIB-DRLA Tablet 100 mg (as mesilate) Oral Glivec
IMATINIB RBXGRP-21079 Capsule 400 mg (as mesilate) Oral Imatinib-APOTEX Capsule 400 mg (as mesilate) Oral IMATINIB-DRLA Tablet 400 mg (as mesilate) Oral Glivec
IMATINIB RBX
Imatinib-Teva
GRP-21080 Capsule 400 mg (as mesilate) Oral Imatinib-APOTEX Capsule 400 mg (as mesilate) Oral IMATINIB-DRLA Tablet 400 mg (as mesilate) Oral Glivec
IMATINIB RBXMacrogol 3350 GRP-17024 Powder for oral solution 510 g Oral OsmoLax Sachets containing powder for oral solution 17 g, 30 Oral Herron ClearLax Meloxicam GRP-15468 Capsule 15 mg Oral APO-Meloxicam
Chem mart Meloxicam
Meloxicam Sandoz
Mobic
Movalis 15
Moxicam
Terry White Chemists MeloxicamTablet 15 mg Oral APO-Meloxicam
Chem mart Meloxicam 15 mg
Meloxiauro 15
Meloxibell
Meloxicam AN
Meloxicam-GA
Meloxicam Ranbaxy
Meloxicam Sandoz
Mobic
Movalis 15
Moxicam 15
Pharmacor Meloxicam 15
Terry White Chemists Meloxicam 15 mgGRP-15658 Capsule 7.5 mg Oral APO-Meloxicam
Chem mart Meloxicam
Meloxicam Sandoz
Mobic
Movalis 7.5
Moxicam
Terry White Chemists MeloxicamTablet 7.5 mg Oral APO-Meloxicam
Chem mart Meloxicam 7.5 mg
Meloxiauro 7.5
Meloxibell
Meloxicam AN
Meloxicam-GA
Meloxicam Ranbaxy
Meloxicam Sandoz
Mobic
Movalis 7.5
Moxicam 7.5
Pharmacor Meloxicam 7.5
Terry White Chemists Meloxicam 7.5 mgMorphine GRP-20890 Injection containing morphine hydrochloride 10 mg in 1 mL Injection Morphine Juno Injection containing morphine sulfate 10 mg in 1 mL Injection Hospira Pty Limited Olanzapine GRP-15492 Tablet 2.5 mg Oral APO-Olanzapine
Chem mart Olanzapine
Lanzek
Olanzacor 2.5
Olanzapine AN
Olanzapine RBX
Olanzapine Sandoz
Olanzapine-DRLA
Ozin 2.5
Terry White Chemists Olanzapine
Zypine
Zyprexa
Tablet 2.5 mg (as benzoate) Oral Olanzapine generichealth 2.5 GRP-15921 Tablet 5 mg Oral APO-Olanzapine
Chem mart Olanzapine
Lanzek
Olanzacor 5
Olanzapine AN
Olanzapine GH
Olanzapine RBX
Olanzapine Sandoz
Olanzapine-DRLA
Ozin 5
Terry White Chemists Olanzapine
Zypine
Zyprexa
Tablet 5 mg (as benzoate) Oral Olanzapine generichealth 5 GRP-15884 Tablet 7.5 mg Oral APO-Olanzapine
Chem mart Olanzapine
Lanzek
Olanzacor 7.5
Olanzapine AN
Olanzapine GH
Olanzapine RBX
Olanzapine Sandoz
Olanzapine-DRLA
Ozin 7.5
Terry White Chemists Olanzapine
Zypine
Zyprexa
Tablet 7.5 mg (as benzoate) Oral Olanzapine generichealth 7.5 GRP-15513 Tablet 10 mg Oral APO-Olanzapine
Chem mart Olanzapine
Lanzek
Olanzacor 10
Olanzapine AN
Olanzapine GH
Olanzapine RBX
Olanzapine Sandoz
Olanzapine-DRLA
Ozin 10
Terry White Chemists Olanzapine
Zypine
Zyprexa
Tablet 10 mg (as benzoate) Oral Olanzapine generichealth 10 Ondansetron GRP-15983 Tablet (orally disintegrating) 4 mg Oral Ondansetron AN ODT
Ondansetron ODT-DRLA
Ondansetron ODT GH
Ondansetron SZ ODT
Onsetron ODT 4
Ondansetron AN ODT
Ondansetron ODT-DRLA
Ondansetron SZ ODT
Onsetron ODT 4
Zilfojim ODT 4
Wafer 4 mg Oral Zofran Zydis GRP-15402 Tablet (orally disintegrating) 8 mg Oral Ondansetron AN ODT
Ondansetron ODT-DRLA
Ondansetron ODT GH
Ondansetron SZ ODT
Onsetron ODT 8
Ondansetron AN ODT
Ondansetron ODT-DRLA
Ondansetron SZ ODT
Onsetron ODT 8
Zilfojim ODT 8
Wafer 8 mg Oral Zofran Zydis Perindopril GRP-15442 Tablet containing perindopril erbumine 4 mg Oral APO-Perindopril
Blooms the Chemist Perindopril
Chem mart Perindopril
Idaprex 4
Indosyl Mono 4
Ozapace
Perindo
Perindopril Actavis 4
Perindopril AN
Perindopril CH
Perindopril generichealth
Terry White Chemists Perindopril
Tablet containing perindopril arginine 5 mg Oral APO-Perindopril Arginine
Coversyl 5mg
PREXUM 5
GRP-15525 Tablet containing perindopril erbumine 8 mg Oral APO-Perindopril
Blooms the Chemist Perindopril
Chem mart Perindopril
Idaprex 8
Indosyl Mono 8
Ozapace
Perindo
Perindopril Actavis 8
Perindopril AN
Perindopril CH
Perindopril generichealth
Terry White Chemists Perindopril
Tablet containing perindopril arginine 10 mg Oral APO-Perindopril Arginine
Coversyl 10mg
PREXUM 10
GRP-15965 Tablet containing perindopril erbumine 2 mg Oral APO-Perindopril
Blooms the Chemist Perindopril
Chem mart Perindopril
Idaprex 2
Indosyl Mono 2
Ozapace
Perindo
Perindopril Actavis 2
Perindopril AN
Terry White Chemists Perindopril
Tablet containing perindopril arginine 2.5 mg Oral APO-Perindopril Arginine
Coversyl 2.5mg
PREXUM 2.5
Perindopril with indapamide GRP-15765 Tablet containing perindopril erbumine 4 mg with indapamide hemihydrate 1.25 mg Oral Chem mart Perindopril/ Indapamide 4/1.25
GenRx Perindopril/ Indapamide 4/1.25
Idaprex Combi 4/1.25
Indosyl Combi 4/1.25
Perindo Combi 4/1.25
Perindopril and Indapamide AN 4/1.25
Perindopril and Indapamide CH 4/1.25
Perindopril Combi Actavis 4/1.25
Perindopril/ Indapamide GH 4/1.25
Terry White Chemists Perindopril/ Indapamide 4/1.25
Tablet containing perindopril arginine 5 mg with indapamide hemihydrate 1.25 mg Oral Coversyl Plus 5mg/1.25mg
Prexum Combi 5/1.25
Ramipril GRP-15431 Capsule 10 mg Oral APO‑Ramipril
Chem mart Ramipril
Prilace 10
Ramace 10 mg
Ramipril AN
Ramipril generichealth
Ramipril Sandoz
Ramipril Winthrop
Terry White Chemists Ramipril
Tritace 10 mg
Tryzan Caps 10
Vascalace Caps 10Tablet 10 mg Oral APO‑Ramipril
Chem mart Ramipril
Ramipril AN
Ramipril Sandoz
Ramipril Winthrop
Terry White Chemists Ramipril
Tritace
Tryzan Tabs 10
Vascalace 10Rizatriptan GRP-17623 Tablet (orally disintegrating) 10 mg (as benzoate) Oral APO-Rizatriptan
Chem mart Rizatriptan
Rizatriptan AN ODT
Rizatriptan ODT GH
Terry White Chemists Rizatriptan
Wafer 10 mg (as benzoate) Oral Maxalt
Rizatriptan Wafers-10mg
Sumatriptan GRP-15928 Tablet 50 mg (as succinate) Oral APO-Sumatriptan
Chem mart Sumatriptan
Imigran
Iptam
Pharmacor Sumatriptan 50
Sumagran Aspen 50
Sumatran
Sumatriptan AN
Sumatriptan RBX
Sumatriptan Sandoz
Sumatriptan generichealth
Terry White Chemists Sumatriptan
Tablet (fast disintegrating) 50 mg (as succinate) Oral Imigran FDT Zoledronic Acid GRP-17614 Injection concentrate for I.V. infusion 4 mg (as monohydrate) in 5 mL Injection APO-Zoledronic Acid
DBL Zoledronic Acid
Zometa
Solution for I.V. infusion 4 mg (as monohydrate) in 100 mL Injection DBL Zoledronic Acid
Zometa
Endnotes
Endnote 1—About the endnotes
The endnotes provide information about this compilation and the compiled law.
The following endnotes are included in every compilation:
Endnote 1—About the endnotes
Endnote 2—Abbreviation key
Endnote 3—Legislation history
Endnote 4—Amendment history
Abbreviation key—Endnote 2
The abbreviation key sets out abbreviations that may be used in the endnotes.
Legislation history and amendment history—Endnotes 3 and 4
Amending laws are annotated in the legislation history and amendment history.
The legislation history in endnote 3 provides information about each law that has amended (or will amend) the compiled law. The information includes commencement details for amending laws and details of any application, saving or transitional provisions that are not included in this compilation.
The amendment history in endnote 4 provides information about amendments at the provision (generally section or equivalent) level. It also includes information about any provision of the compiled law that has been repealed in accordance with a provision of the law.
Editorial changes
The Legislation Act 2003 authorises First Parliamentary Counsel to make editorial and presentational changes to a compiled law in preparing a compilation of the law for registration. The changes must not change the effect of the law. Editorial changes take effect from the compilation registration date.
If the compilation includes editorial changes, the endnotes include a brief outline of the changes in general terms. Full details of any changes can be obtained from the Office of Parliamentary Counsel.
Misdescribed amendments
A misdescribed amendment is an amendment that does not accurately describe the amendment to be made. If, despite the misdescription, the amendment can be given effect as intended, the amendment is incorporated into the compiled law and the abbreviation “(md)” added to the details of the amendment included in the amendment history.
If a misdescribed amendment cannot be given effect as intended, the abbreviation “(md not incorp)” is added to the details of the amendment included in the amendment history.
Endnote 2—Abbreviation key
ad = added or inserted o = order(s) am = amended Ord = Ordinance amdt = amendment orig = original c = clause(s) par = paragraph(s)/subparagraph(s) C[x] = Compilation No. x /sub‑subparagraph(s) Ch = Chapter(s) pres = present def = definition(s) prev = previous Dict = Dictionary (prev…) = previously disallowed = disallowed by Parliament Pt = Part(s) Div = Division(s) r = regulation(s)/rule(s) ed = editorial change reloc = relocated exp = expires/expired or ceases/ceased to have renum = renumbered effect rep = repealed F = Federal Register of Legislation rs = repealed and substituted gaz = gazette s = section(s)/subsection(s) LA = Legislation Act 2003 Sch = Schedule(s) LIA = Legislative Instruments Act 2003 Sdiv = Subdivision(s) (md) = misdescribed amendment can be given SLI = Select Legislative Instrument effect SR = Statutory Rules (md not incorp) = misdescribed amendment Sub‑Ch = Sub‑Chapter(s) cannot be given effect SubPt = Subpart(s) mod = modified/modification underlining = whole or part not No. = Number(s) commenced or to be commenced Endnote 3—Legislation history
Name Registration Commencement Application, saving and transitional provisions PB 71 of 2012 28 Sept 2012 (F2012L01982) 1 Oct 2012 (s 2) PB 93 of 2012 29 Nov 2012 (F2012L02291) 1 Dec 2012 (s 2) — PB 108 of 2012 18 Dec 2012 (F2012L02512) 1 Jan 2013 (s 2) — PB 1 of 2013 10 Jan 2013 (F2013L00039) 1 Feb 2013 (s 2) — PB 4 of 2013 21 Jan 2013 (F2013L00072) 22 Jan 2013 (s 2) — PB 8 of 2013 14 Feb 2013 (F2013L00185) 1 Mar 2013 (s 2) — PB 14 of 2013 27 Mar 2013 (F2013L00566) 1 Apr 2013 (s 2) — PB 21 of 2013 24 Apr 2013 (F2013L00685) 1 May 2013 (s 2) — PB 29 of 2013 24 May 2013 (F2013L00843) 1 June 2013 (s 2) — PB 35 of 2013 5 June 2013 (F2013L00922) 1 July 2013 (s 2) — PB 39 of 2013 21 June 2013 (F2013L01096) 1 July 2013 (s 2) — PB 40 of 2013 29 July 2013 (F2013L01460) 1 Aug 2013 (s 2) — PB 53 of 2013 16 Aug 2013 (F2013L01580) 1 Sept 2013 (s 2) — PB 61 of 2013 10 Sept 2013 (F2013L01682) 1 Oct 2013 (s 2) — PB 69 of 2013 4 Oct 2013 (F2013L01768) 1 Nov 2013 (s 2) — PB 74 of 2013 29 Nov 2013 (F2013L02013) 1 Dec 2013 (s 2) — PB 88 of 2013 20 Dec 2013 (F2013L02170) 1 Jan 2014 (s 2) — PB 1 of 2014 10 Jan 2014 (F2014L00051) 1 Feb 2014 (s 2) — PB 9 of 2014 17 Feb 2014 (F2014L00147) 1 Mar 2014 (s 2) — PB 17 of 2014 26 Mar 2014 (F2014L00342) 1 Apr 2014 (s 2) — PB 27 of 2014 11 Apr 2014 (F2014L00399) 1 May 2014 (s 2) — PB 36 of 2014 21 May 2014 (F2014L00588) 1 June 2014 (s 2) — PB 45 of 2014 20 June 2014 (F2014L00763) 1 July 2014 (s 2) — PB 51 of 2014 1 July 2014 (F2014L00921) 1 July 2014 (s 2) — PB 52 of 2014 31 July 2014 (F2014L01058) 1 Aug 2014 (s 2) — PB 61 of 2014 25 Aug 2014 (F2014L01121) 1 Sept 2014 (s 2) — PB 72 of 2014 30 Sept 2014 (F2014L01298) 1 Oct 2014 (s 2) — PB 82 of 2014 24 Oct 2014 (F2014L01395) 1 Nov 2014 (s 2) — PB 88 of 2014 28 Nov 2014 (F2014L01602) 1 Dec 2014 (s 2) — PB 101 of 2014 22 Dec 2014 (F2014L01780) 1 Jan 2015 (s 2) — PB 109 of 2014 23 Dec 2014 (F2014L01795) 1 Jan 2015 (s 2) — PB 1 of 2015 14 Jan 2015 (F2015L00040) 1 Feb 2015 (s 2) — PB 10 of 2015 25 Feb 2015 (F2015L00205) 1 Mar 2015 (s 2) — PB 26 of 2015 26 Mar 2015 (F2015L00342) 1 Apr 2015 (s 2) — PB 39 of 2015 24 Apr 2015 (F2015L00595) 1 May 2015 (s 2) — PB 47 of 2015 29 May 2015 (F2015L00762) 1 June 2015 (s 2) — PB 55 of 2015 30 June 2015 (F2015L01058) 1 July 2015 (s 2) — PB 68 of 2015 31 July 2015 (F2015L01212) 1 Aug 2015 (s 2) — PB 78 of 2015 28 Aug 2015 (F2015L01351) 1 Sept 2015 (s 2) — PB 90 of 2015 29 Sept 2015 (F2015L01520) 1 Oct 2015 (s 2) — PB 101 of 2015 27 Oct 2015 (F2015L01701) 1 Nov 2015 (s 2) — PB 107 of 2015 30 Nov 2015 (F2015L01878) 1 Dec 2015 (s 2) — PB 117 of 2015 24 Dec 2015 (F2015L02141) 1 Jan 2016 (s 2) — PB 1 of 2016 1 Feb 2016 (F2016L00075) 1 Feb 2016 (s 2) — PB 11 of 2016 23 Feb 2016 (F2016L00136) 1 Mar 2016 (s 2) — PB 18 of 2016 1 Apr 2016 (F2016L00470) 1 Apr 2016 (s 2) — PB 29 of 2016 29 Apr 2016 (F2016L00604) 1 May 2016 (s 2) — PB 41 of 2016 30 May 2016 (F2016L00856) 1 June 2016 (s 2) — PB 52 of 2016 22 June 2016 (F2016L01056) 1 July 2016 (s 2) — PB 62 of 2016 19 July 2016 (F2016L01185) 1 Aug 2016 (s 2) — PB 72 of 2016 18 Aug 2016 (F2016L01296) 1 Sept 2016 (s 2) — PB 81 of 2016 30 Sept 2016 (F2016L01560) 1 Oct 2016 (s 2) — PB 90 of 2016 31 Oct 2016 (F2016L01689) 1 Nov 2016 (s 2) — PB 97 of 2016 30 Nov 2016 (F2016L01832) 1 Dec 2016 (s 2) — Endnote 4—Amendment history
Provision affected How affected s 2........................................ rep LIA s 48D s 3........................................ rep LIA s 48C s 4........................................ am PB 93 of 2012; PB 26 and 55 of 2015; PB 11 of 2016 s 11...................................... am PB 26 of 2015; PB 29 of 2016 s 12...................................... am PB 26 of 2015; PB 29 of 2016 s 13...................................... am PB 26 of 2015; PB 29 of 2016 s 14...................................... am PB 26 of 2015 Schedule 1 Schedule 1........................... am PB 93 and 108 of 2012; PB 1, 4, 8, 14, 21, 29, 35, 39, 40, 53, 61, 69, 74 and 88 of 2013; PB 1, 9, 17, 27, 36, 45, 51, 52, 61, 72, 82, 88, 101 and 109 of 2014; PB 1, 10 and 26 of 2015; PB 39, 47, 55, 68 (Sch 1 item (9)(e) md), 78, 90, 101, 107 and 117 of 2015; PB 1, 11, 18, 29, 41, 52, 62, 72, 81 (Sch 1 item 56 md), 90 and 97 of 2016 Schedule 2 Schedule 2........................... am PB 68 and 90 of 2015 Schedule 3 Schedule 3........................... am PB 93 and 108 of 2012; PB 1, 8, 14, 29, 40, 61, 74 and 88 of 2013; PB 1, 9, 17, 36, 45, 52, 61, 72, 82, 88 and 101 of 2014; PB 1, 10, 26, 39, 47, 55, 68, 78, 90, 101, 107 and 117 of 2015; PB 1, 11, 18, 41, 52, 62, 81 and 97 of 2016 Schedule 4 Schedule 4........................... am PB 93 and 108 of 2012; PB 1, 8, 14, 21, 29, 35, 40, 53, 61, 69, 74 and 88 of 2013; PB 1, 9, 17, 27, 36, 45, 52, 61, 72, 82, 88 and 101 of 2014; PB 1, 10, 26, 39, 47, 55, 68, 78, 90, 101, 107 and 117 of 2015; PB 1, 11, 18, 29, 41, 52, 62, 72, 81, 90 and 97 of 2016 Schedule 5 Schedule 5........................... ad PB 107, 2015 am PB 1, 11, 18, 29, 41, 52, 62, 72, 81, 90 and 97 of 2016
0
0
0